

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/57059 A1(51) International Patent Classification: C07H 21/04,
A61K 48/00, C12N 15/09, 15/00, C12Q 1/68(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number: PCT/US01/02939

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 30 January 2001 (30.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/496,694 2 February 2000 (02.02.2000) US(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): ISIS
PHARMACEUTICALS, INC. [US/US]; 2292 Faraday
Avenue, Carlsbad, CA 92008 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/57059 A1

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BENNETT, C.,
Frank [US/US]; 1347 Cassins Street, Carlsbad, CA 92008
(US). ACKERMANN, Elizabeth, J. [US/US]; 519 Santa
Victoria, Solana Beach, CA 92075 (US). SWAYZE, Eric,
E. [US/US]; 7789 Palenque Street, Carlsbad, CA 92009
(US). COWSERT, Lex, M. [US/US]; 3008 Newshire
Street, Carlsbad, CA 92008 (US).

(54) Title: ANTISENSE MODULATION OF SURVIVIN EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.

ANTISENSE MODULATION OF SURVIVIN EXPRESSION

FIELD OF THE INVENTION

The present invention provides compositions and methods
5 for modulating the expression of Survivin. In particular,
this invention relates to antisense compounds, particularly
oligonucleotides, specifically hybridizable with nucleic acids
encoding human Survivin. Such oligonucleotides have been
shown to modulate the expression of Survivin.

10 BACKGROUND OF THE INVENTION

A hallmark feature of cancerous cells is uncontrolled
proliferation. Among the differences that have been
discovered between tumor and normal cells is resistance to the
process of programmed cell death, also known as apoptosis.
15 (Ambrosini et al., *Nat. Med.*, 1997, 3, 917-921). Apoptosis
is a process multicellular organisms have evolved to prevent
uncontrolled cell proliferation as well as to eliminate cells
that have become sick, deleterious, or are no longer
necessary. The process of apoptosis involves a multistep
20 cascade in which cells are degraded from within through the
concerted action of proteolytic enzymes and DNA endonucleases,
resulting in the formation of apoptotic bodies that are then
removed by scavenger cells. Research to date has shown that
much of the intracellular degradation is carried out through
25 the action of the caspases, a family of proteolytic enzymes
that cleave adjacent to aspartate residues (Cohen,
Biochemistry Journal, 1997, 326, 1-16).

The finding that most tumor cells display resistance to the apoptotic process has led to the view that therapeutic strategies aimed at attenuating the resistance of tumor cells to apoptosis could represent a novel means to halt the spread of neoplastic cells (Ambrosini et al., *Nat. Med.*, 1997, 3, 917-921). One of the mechanisms through which tumor cells are believed to acquire resistance to apoptosis is by overexpression of Survivin, a recently described member of the IAP (inhibitor of apoptosis) caspase inhibitor family. To date, overexpression of Survivin has been detected in tumors of the lung, colon, pancreas, prostate, breast, stomach, non-Hodgkin's lymphoma, and neuroblastoma (Adida et al., *Lancet*, 1998, 351, 882-883; Ambrosini et al., *Nat. Med.*, 1997, 3, 917-921; Lu et al., *Cancer Res.*, 1998, 58, 1808-1812). A more detailed analysis has been performed in neuroblastoma where it was found that Survivin overexpression segregated with tumor histologies known to associate with poor prognosis (Adida et al., *Lancet*, 1998, 351, 882-883). Finally, Ambrosini et al. describe transfection of HeLa cells with an expression vector containing a 708 nt fragment of the human cDNA encoding effector cell protease receptor 1 (EPR-1), the coding sequence of which is extensively complementary to the coding strand of Survivin (Ambrosini et al., *J. Bio. Chem.*, 1998, 273, 11177-11182) and which potentially acts as a Survivin antisense RNA. This construct caused a reduction in cell viability. Methods for modulating apoptosis and for reducing the severity of a pathological state mediated by Survivin using agents that modulate amounts or activity of Survivin are disclosed in WO 98/22589, which also discloses the EPR-1 coding strand/Survivin antisense construct described by Ambrosini et al., *supra*.

Survivin has recently been found to play a role in cell cycle regulation. It has been found to be expressed in the G2/M phase of the cell cycle in a cycle-regulated manner, and

associates with microtubules of the mitotic spindle. Disruption of this interaction results in loss of Survivin's anti-apoptotic function and increased caspase-3 activity during mitosis. Caspase-3 is associated with apoptotic cell death. It is therefore believed that Survivin may counteract a default induction of apoptosis in G2/M phase. It is believed that the overexpression of Survivin in cancer may overcome this apoptotic checkpoint, allowing undesired survival and division of cancerous cells. The Survivin antisense construct described by Ambrosini above was found to downregulate endogenous Survivin in HeLa cells and to increase caspase-3-dependent apoptosis in cells in G2/M phase. Li et al., Nature, 1998, 396, 580-584.

As a result of these advances in the understanding of apoptosis and the role that Survivin expression is believed to play in conferring a growth advantage to a wide variety of tumor cell types, there is a great desire to provide compositions of matter which can modulate the expression of Survivin. It is greatly desired to provide methods of diagnosis and detection of nucleic acids encoding Survivin in animals. It is also desired to provide methods of diagnosis and treatment of conditions arising from Survivin expression. In addition, improved research kits and reagents for detection and study of nucleic acids encoding Survivin are desired.

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of Survivin. Consequently, there is a long-felt need for agents capable of effectively inhibiting Survivin expression in tumor cells. Antisense oligonucleotides against Survivin may therefore prove to be uniquely useful in a number of therapeutic, diagnostic and research applications.

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted

to a nucleic acid encoding Survivin, and which modulate the expression of Survivin. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the
5 expression of Survivin in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or
10 condition associated with expression of Survivin by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

15 The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Survivin, ultimately modulating the amount of Survivin produced. This is accomplished by providing antisense
20 compounds which specifically hybridize with one or more nucleic acids encoding Survivin. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Survivin" encompass DNA encoding Survivin, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from
25 such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as
30 "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of

the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Survivin.

5 In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

10 It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated.

15 This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding Survivin. The

20 targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the

25 region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon

30 is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation

35 codon" and "start codon" can encompass many codon sequences,

even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start
5 codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation
10 codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding Survivin, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of
15 three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about
20 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either
25 direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination
30 codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the
35 translation initiation codon of an mRNA or corresponding

nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation
5 termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap
10 structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as
15 "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are
20 particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that
25 introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently
30 complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary
35 nucleoside or nucleotide bases. For example, adenine and

thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, or in the case of *in vitro* assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish

between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also
5 harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical
10 trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term
15 "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as
20 oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and
25 increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The
30 antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Preferred
35 embodiments comprise at least an 8-nucleobase portion of a

sequence of an antisense compound which inhibits expression of Survivin. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates,

phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs
5 of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the
10 preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677;
15 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are
20 formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from
25 the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino
30 backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not
35 limited to, U.S. Patents 5,034,506; 5,166,315; 5,185,444;

5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which
is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the
sugar and the internucleoside linkage, i.e., the backbone, of
the nucleotide units are replaced with novel groups. The base
10 units are maintained for hybridization with an appropriate
nucleic acid target compound. One such oligomeric compound,
an oligonucleotide mimetic that has been shown to have
excellent hybridization properties, is referred to as a
peptide nucleic acid (PNA). In PNA compounds, the sugar-
15 backbone of an oligonucleotide is replaced with an amide
containing backbone, in particular an aminoethylglycine
backbone. The nucleobases are retained and are bound directly
or indirectly to aza nitrogen atoms of the amide portion of
the backbone. Representative United States patents that teach
20 the preparation of PNA compounds include, but are not limited
to, U.S. Patents 5,539,082; 5,714,331; and 5,719,262, each of
which is herein incorporated by reference. Further teaching
of PNA compounds can be found in Nielsen et al., *Science*,
1991, 254, 1497-1500.

25 Most preferred embodiments of the invention are
oligonucleotides with phosphorothioate backbones and
oligonucleosides with heteroatom backbones, and in particular
-CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene
(methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-
30 N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native
phosphodiester backbone is represented as -O-P-O-CH₂-] of the
above referenced U.S. Patent 5,489,677, and the amide
backbones of the above referenced U.S. Patent 5,602,240. Also
preferred are oligonucleotides having morpholino backbone
35 structures of the above-referenced U.S. Patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nNH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH₂)_nN(CH₃)₂ group, also known as 2'-DMAOE, as described in United States patent application Serial Number 09/016,520, filed on January 30, 1998, which is commonly owned with the instant application and the contents of which are herein incorporated by reference.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal

nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patents 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U. S. Patent 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15,

Antisense Research and Applications, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These
5 include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyl-adenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S.,
10 Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

15 Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent 3,687,808, as well as U.S. Patents 4,845,205; 5,130,302; 5,134,066; 5,175,273;
20 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; and 5,750,692, each of which is herein incorporated by reference.

Another modification of the oligonucleotides of the
25 invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et
30 al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Let.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Let.*, 1993, 3, 2765-2770), a

thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; 5 Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a 10 polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or 15 hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Patents 4,828,979; 4,948,882; 20 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 25 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 30 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one

of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Patents 5,013,830; 5,149,797; 5,220,007;

5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Patents 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to

an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the
5 compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the
10 action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al.,
15 published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not
20 impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the
25 like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-
30 19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the
35 free acid in the conventional manner. The free acid forms

differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable

pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

5 For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with
10 inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid,
15 malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from
20 elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder
25 which can be treated by modulating the expression of Survivin is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically
30 acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for
35 research and diagnostics, because these compounds hybridize

to nucleic acids encoding Survivin, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding Survivin can be
5 detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Survivin in a sample may also be
10 prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of
15 ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including
20 by nebulizer; intratracheal, intranasal, epidermal, intradermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection, drip or infusion; or intracranial, e.g., intrathecal or
25 intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments,
30 lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, 5 dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited 10 to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions and/or formulations comprising the oligonucleotides of the present invention may also include penetration enhancers in order to enhance the 15 alimentary delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8, 91-192; 20 Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33). One or more penetration enhancers from one or more of these broad categories may be included.

Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric 25 acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (a.k.a. 1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arichidonic acid, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, 30 acylcholines, mono- and di-glycerides and physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug*

Carrier Systems, 1990, 7:1, 1-33; El-Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654). Examples of some presently preferred fatty acids are sodium caprate and sodium laurate, used singly or in combination at concentrations of 0.5 to 5%.

5 The physiological roles of bile include the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996, pages 934-935).
10 Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Examples of presently preferred bile salts are chenodeoxycholic acid
15 (CDCA) and/or ursodeoxycholic acid (UDCA), generally used at concentrations of 0.5 to 2%.

Complex formulations comprising one or more penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex formulations.
20 Preferred combinations include CDCA combined with sodium caprate or sodium laurate (generally 0.5 to 5%).

Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and
25 homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 92-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33; Buur et al., *J. Control*
30 *Rel.*, 1990, 14, 43-51). Chelating agents have the added advantage of also serving as DNase inhibitors.

Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., *Critical Reviews in Therapeutic Drug*

Carrier Systems, 1991, 8:2, 92-191); and perfluorochemical emulsions, such as FC-43 (Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252-257).

Non-surfactants include, for example, unsaturated cyclic
5 ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives
(Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 92-191); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*,
10 1987, 39, 621-626).

As used herein, "carrier compound" refers to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the
15 bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result
20 in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioated
25 oligonucleotide in hepatic tissue is reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*,
30 1996, 6, 177-183).

In contrast to a carrier compound, a "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more

nucleic acids to an animal. The pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc., when combined with a
5 nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers
10 (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated
15 vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g., starch, sodium starch glycolate, etc.); or wetting agents (e.g., sodium lauryl sulphate, etc.). Sustained release oral delivery systems and/or enteric coatings for orally
20 administered dosage forms are described in U.S. Patents 4,704,295; 4,556,552; 4,309,406; and 4,309,404.

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established
25 usage levels. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the
30 composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the invention.

Regardless of the method by which the antisense compounds of the invention are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the *in vivo* stability of the compounds and/or to
5 target the compounds to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and
10 lipid:oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layer(s) made up of lipids arranged in a bilayer configuration (see, generally,
15 Chonn et al., *Current Op. Biotech.*, 1995, 6, 698-708).

Certain embodiments of the invention provide for liposomes and other compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples
20 of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone,
25 hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine,
30 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide,
35 cisplatin and diethylstilbestrol (DES). See, generally, *The*

Merck Manual of Diagnosis and Therapy, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide),
5 sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide).

10 Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck*
15 *Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

20 In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Examples of antisense
25 oligonucleotides include, but are not limited to, those directed to the following targets as disclosed in the indicated U.S. Patents, or pending U.S. applications, which are commonly owned with the instant application and are hereby incorporated by reference, or the indicated published PCT
30 applications: raf (WO 96/39415, WO 95/32987 and U.S. Patents 5,563,255 and 5,656,612), the p120 nucleolar antigen (WO 93/17125 and U.S. Patent 5,656,743), protein kinase C (WO 95/02069, WO 95/03833 and WO 93/19203), multidrug resistance-associated protein (WO 95/10938 and U.S. Patent 5,510,239),

subunits of transcription factor AP-1 (pending application U.S. Serial No. 08/837,201, filed April 14, 1997), Jun kinases (pending application U.S. Serial No. 08/910,629, filed August 13, 1997), MDR-1 (multidrug resistance glycoprotein; pending application U.S. Serial No. 08/731,199, filed September 30, 1997), HIV (U.S. Patents 5,166,195 and 5,591,600), herpesvirus (U.S. Patents 5,248,670 and 5,514,577), cytomegalovirus (U.S. Patents 5,442,049 and 5,591,720), papillomavirus (U.S. Patent 5,457,189), intercellular adhesion molecule-1 (ICAM-1) (U.S. Patent 5,514,788), 5-lipoxygenase (U.S. Patent 5,530,114) and influenza virus (U.S. Patent 5,580,767). Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging

from 0.01 μ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred
5 embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside phosphoramidites for oligonucleotide synthesis

10 deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared
15 as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

20 Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

25 2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and U. S. Patent 5,670,633, herein incorporated by
30 reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing

commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2 -displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-
5 beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and
10 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and
15 conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by
20 treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished
25 by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-Fluorodeoxycytidine

30 2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard

procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2

L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/Acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

15 **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**
2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 hours using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were

filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, 5 dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) 10 in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with 15 NH₃ gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was 20 evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic 25 anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃, 30 (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure

product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

5 N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture
10 was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH_2Cl_2 (300 mL), and the extracts were combined, dried over MgSO_4 , and
15 concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

20 **2'-(Aminooxyethyl) nucleoside amidites and 2'-(dimethylaminooxyethyl) nucleoside amidites**

Aminooxyethyl and dimethylaminooxyethyl amidites are prepared as per the methods of United States patent applications serial number 10/037,143, filed February 14, 1998, and serial number 09/016,520, filed January 30, 1998,
25 each of which is commonly owned with the instant application and is herein incorporated by reference.

Example 2

Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O)
30 oligonucleotides are synthesized on an automated DNA

synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation
5 bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in
10 concentrated ammonium hydroxide at 55°C (18 hours), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

15 Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050,
20 herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as
25 described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein
30 incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

5 Oligonucleoside synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked
10 oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared
15 as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and
20 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

25 PNA synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23.
30 They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5**Synthesis of chimeric oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

**[2'-O-Me] - [2'-deoxy] - [2'-O-Me] chimeric
phosphorothioate oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hours at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hours at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by

rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

5 [2'-O-(2-Methoxyethyl)]-[2'-deoxy]-[2'-O-(Methoxyethyl)] chimeric phosphorothioate oligonucleotides

 [2'-O-(2-methoxyethyl)]-[2'-deoxy]-[-2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were
10 prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

 [2'-O-(2-Methoxyethyl)Phosphodiester]-[2'-deoxy Phosphorothioate]-[2'-O-(2-Methoxyethyl)
15 Phosphodiester] chimeric oligonucleotides

 [2'-O-(2-methoxyethyl phosphodiester)]-[2'-deoxy phosphorothioate]-[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution
20 of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate
25 the phosphorothioate internucleotide linkages for the center gap.

 Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U. S. Patent 5,623,065, herein
30 incorporated by reference.

Example 6**Oligonucleotide isolation**

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7**Oligonucleotide synthesis - 96 well plate format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

Oligonucleotide analysis - 96 well plate format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but other cell types can be routinely used.

T-24 cells:

The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in 5 complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were 10 routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be 15 seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained 20 from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 25 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained 30 from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by

the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

10 3T3-L1 cells:

The mouse embryonic adipocyte-like cell line 3T3-L1 was obtained from the American Type Culture Collection (Manassas, VA). 3T3-L1 cells were routinely cultured in DMEM, high glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 80% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 4000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

25 Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4

hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal
5 oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**,
SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls
10 shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCAAGGA**,
SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls
15 shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of H-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new
20 oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent
25 experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10

Analysis of oligonucleotide inhibition of Survivin expression

Antisense modulation of Survivin expression can be
30 assayed in a variety of ways known in the art. For example, Survivin mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR),

or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current*
5 *Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996.
10 Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are also known in the art.
15 Survivin protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Survivin can be identified and obtained from a variety of
20 sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*,
25 Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.
30 Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found

at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

10 Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for
15 cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then
20 incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the
25 final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to
30 a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12**Total RNA isolation**

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μ L water.

Example 13**Real-time quantitative PCR analysis of Survivin mRNA levels**

Quantitation of Survivin mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which

allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are
5 quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies
10 Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes
15 are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle,
20 cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the
25 fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is
30 used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding
25 μ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM $MgCl_2$, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of
35

forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 µL poly(A) mRNA solution. The RT reaction was carried out by 5 incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). Probes and primers to human Survivin 10 were designed to hybridize to a human Survivin sequence, using published sequence information (GenBank accession number U75285, incorporated herein as SEQ ID NO:3). For human Survivin the PCR primers were:

forward primer: AAGGACCACCGCATCTCTACA (SEQ ID NO: 4)
15 reverse primer: CCAAGTCTGGCTCGTTCTCAGT (SEQ ID NO: 5) and the PCR probe was: FAM-CGAGGCTGGCTTCATCCACTGCC-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human 20 GAPDH the PCR primers were:
forward primer: GAAGGTGAAGGTCTGGAGTC (SEQ ID NO: 7)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is 25 the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Probes and primers to mouse Survivin were designed to hybridize to a mouse Survivin sequence, using published sequence information (GenBank accession number AB013819, 30 incorporated herein as SEQ ID NO:10). For mouse Survivin the PCR primers were:

forward primer: CCGAGAACGAGCCTGATTTG (SEQ ID NO:11)
reverse primer: GGGAGTGCTTTCTATGCTCCTCTA (SEQ ID NO: 12) and the PCR probe was: FAM-TAAGGAATTGGAAGGCTGGGAACCCG-TAMRA

(SEQ ID NO: 13) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For mouse GAPDH the PCR primers were:

- 5 forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO: 14)
reverse primer: GGGTCTCGCTCCTGGAAGCT (SEQ ID NO: 15) and the
PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTCATC- TAMRA 3'
(SEQ ID NO: 16) where JOE (PE-Applied Biosystems, Foster City,
CA) is the fluorescent reporter dye) and TAMRA (PE-Applied
10 Biosystems, Foster City, CA) is the quencher dye.

Example 14

Northern blot analysis of Survivin mRNA levels

- Eighteen hours after antisense treatment, cell
15 monolayers were washed twice with cold PBS and lysed in 1 mL
RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was
prepared following manufacturer's recommended protocols.
Twenty micrograms of total RNA was fractionated by
electrophoresis through 1.2% agarose gels containing 1.1%
20 formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon,
OH). RNA was transferred from the gel to HYBOND™-N+ nylon
membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by
overnight capillary transfer using a Northern/Southern
Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).
25 RNA transfer was confirmed by UV visualization. Membranes
were fixed by UV cross-linking using a STRATALINKER™ UV
Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then
robed using QUICKHYB™ hybridization solution (Stratagene, La
Jolla, CA) using manufacturer's recommendations for stringent
30 conditions.

To detect human Survivin, a human Survivin specific
probe was prepared by PCR using the forward primer
AAGGACCACCGCATCTCTACA (SEQ ID NO: 4) and the reverse primer
CCAAGTCTGGCTCGTTCTCAGT (SEQ ID NO: 5). To normalize for

variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse Survivin, a mouse Survivin specific
5 probe was prepared by PCR using the forward primer
CCGAGAACGAGCCTGATTTG (SEQ ID NO:11) and the reverse primer
GGGAGTGCTTTCTATGCTCCTCTA (SEQ ID NO: 12). To normalize for
variations in loading and transfer efficiency membranes were
stripped and probed for mouse glyceraldehyde-3-phosphate
10 dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Example 15

Antisense inhibition of Survivin expression- phosphorothioate oligodeoxynucleotides

In accordance with the present invention, a series of
15 oligonucleotides were designed to target different regions of
the human Survivin RNA, using published sequences (GenBank
accession number U75285, incorporated herein as SEQ ID NO: 3).
The oligonucleotides are shown in Table 1. Target sites are
indicated by nucleotide numbers, as given in the sequence
20 source reference (Genbank accession no. U75285), to which the
oligonucleotide binds. All compounds in Table 1 are
oligodeoxynucleotides with phosphorothioate backbones
(internucleoside linkages) throughout. All cytodines are 5-
methylcytidines. The compounds were analyzed for effect on
25 Survivin mRNA levels by quantitative real-time PCR as
described in other examples herein. Data are averages from
three experiments. If present, "N.D." indicates "no data".

Table 1
Inhibition of human Survivin mRNA levels by
phosphorothioate oligodeoxynucleotides

	ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
5	23652	5' UTR	1	gcgattcaaattctggcg	0	17
	23653	5' UTR	19	cctctgccaacgggtccc	4	18
	23654	5' UTR	75	tgagaaagggctgccagg	46	19
	23655	5' UTR	103	ttcttgaatgtagagatg	0	20
	23656	5' UTR	128	ggcgcagccctccaagaa	38	21
10	23657	Coding	194	caagtctggctcggtctc	0	22
	23658	Coding	226	tccagctccttgaagcag	32	23
	23659	Coding	249	ggtcgtcatctggctccc	36	24
	23660	Coding	306	gcttcttgacagaaagga	35	25
	23661	Coding	323	ggttaattcttcaaactg	0	26
15	23662	Coding	363	tcttggctctttctctgt	34	27
	23663	Coding	393	tcttattgttggtttcct	0	28
	23664	Coding	417	tcgcagtttctcctcaatt	37	29
	23665	Coding	438	cgatggcacggcgactt	72	30
	23666	Coding	511	cctggaagtggcgagcc	16	31
20	23667	Coding	542	acaggaaggctggaggca	70	32
	23668	Coding	587	tttgaaaatgttgatctc	8	33
	23669	Coding	604	acagttgaaacatctaatt	0	34
	23670	Coding	625	ctttcaagacaaaacagg	0	35
	23671	Coding	650	acaggcagaagcacctct	0	36
25	23672	Coding	682	aagcagccactgttacca	64	37
	23673	Coding	700	aaagagagagagagagag	18	38
	23674	Coding	758	tccctcacttctcacctg	29	39
	23675	3' UTR	777	agggacactgccttcttc	43	40
	23676	3' UTR	808	ccacgcgaacaaagctgt	62	41
30	23677	3' UTR	825	actgtggaaggctctgcc	0	42
	23678	3' UTR	867	aggactgtgacagcctca	62	43
	23679	3' UTR	901	tcagattcaacaggcacc	0	44
	23680	3' UTR	1016	attctctcatcacacaca	26	45
	23681	3' UTR	1054	tgttggttaaacagtagag	0	46
35	23682	3' UTR	1099	tgtgctattctgtgaatt	20	47
	23683	3' UTR	1137	gacttagaatggctttgt	37	48
	23684	3' UTR	1178	ctgtctcctcatccacct	41	49
	23685	3' UTR	1216	aaaaggagtatctgccag	39	50
	23686	3' UTR	1276	gaggagcggccagcatgt	47	51
40	23687	3' UTR	1373	ggctgacagacacacggc	41	52

23688	3' UTR	1405	ccgtgtggagaacgtgac	22	53
23689	3' UTR	1479	tacgccagacttcagccc	1	53
23690	3' UTR	1514	atgacagggaggagggcg	0	53
23691	3' UTR	1571	gccgagatgacctccaga	66	53

5 As shown in Table 1, SEQ ID NOs 19, 21, 23, 24, 25, 27, 29, 30, 32, 37, 40, 41, 43, 48, 49, 50, 51, 52 and 56 demonstrated at least 30% inhibition of Survivin expression in this assay and are therefore preferred.

Example 16

10 Antisense inhibition of Survivin expression- phosphorothioate 2'-MOE gapmer oligonucleotides

In accordance with the present invention, a second series of oligonucleotides targeted to human Survivin were synthesized. The oligonucleotide sequences are shown in Table 15 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. U75285), to which the oligonucleotide binds.

All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central 20 "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. 25 All cytidine residues are 5-methylcytidines.

Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, "N.D." indicates "no data".

Table 2

Inhibition of human Survivin mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

	ISIS#	REGION	TARGET SITE	SEQUENCE	%	SEQ ID NO.
5	23692	5' UTR	1	gcgattcaaattctggcgg	22	57
	23693	5' UTR	19	cctctgccaacgggtccc	15	58
	23694	5' UTR	75	tgagaaagggtgccagg	11	59
	23695	5' UTR	103	ttcttgaaatgtagagatg	37	60
10	23696	5' UTR	128	ggcgcagccctccaagaa	16	61
	23697	Coding	194	caagtctggctcggttctc	17	62
	23698	Coding	226	tccagctccttgaagcag	0	63
	23699	Coding	249	ggtcgtcatctggctccc	19	64
	23700	Coding	306	gcttcttgacagaaagga	35	65
15	23701	Coding	323	gggttaattcttcaaaactg	15	66
	23702	Coding	363	tcttggtcttttctctgt	8	67
	23703	Coding	393	tcttattggttggtttcct	41	68
	23704	Coding	417	tgcagtttccctcaaatt	24	69
	23705	Coding	438	cgatggcacggcgactt	72	70
20	23706	Coding	511	cctggaagtgggtgcagcc	4	71
	23707	Coding	542	acaggaaggctgggtggca	48	72
	23708	Coding	587	tttgaaaatggtgatctc	2	73
	23709	Coding	604	acagttgaaacatctaatt	28	74
	23710	Coding	625	ctttcaagacaaaacagg	0	75
25	23711	Coding	650	acaggcagaagcacctct	38	76
	23712	Coding	682	aagcagccactgttacca	27	77
	23713	Coding	700	aaagagagagagagagag	0	78
	23714	Coding	758	tccctcacttctcacctg	0	79
	23715	3' UTR	777	agggacactgccttcttc	44	80
30	23716	3' UTR	808	ccacgcgaacaaagctgt	25	81
	23717	3' UTR	825	actgtggaaggctctgcc	8	82
	23718	3' UTR	867	aggactgtgacagcctca	49	83
	23719	3' UTR	901	tcagattcaacaggcacc	0	84
	23720	3' UTR	1016	attctctcatcacacaca	0	85
35	23721	3' UTR	1054	tgttggttaaacagtagag	0	86
	23722	3' UTR	1099	tgtgctattctgtgaatt	80	87
	23723	3' UTR	1137	gacttagaatggctttgt	44	88
	23724	3' UTR	1178	ctgtctcctcatccacct	27	89
	23725	3' UTR	1216	aaaaggagtatctgccag	21	90
40	23726	3' UTR	1276	gaggagcggccagcatgt	39	91

23727	3' UTR	1373	ggctgacagacacacggc	45	92
23728	3' UTR	1405	ccgtgtggagaacgtgac	24	93
23729	3' UTR	1479	tacgccagacttcagccc	25	94
23730	3' UTR	1514	atgacagggaggaggcg	0	95
23731	3' UTR	1571	gccgagatgacctccaga	19	96

As shown in Table 2, SEQ ID NOs 60, 65, 68, 70, 72, 76, 80, 83, 87, 88, 91 and 92 demonstrated at least 30% inhibition of Survivin expression in this experiment and are therefore preferred.

10 Example 17

Antisense inhibition of Survivin expression- phosphorothioate 2'-MOE gapmer oligonucleotides

In accordance with the present invention, a third series of oligonucleotides targeted to human Survivin mRNA were synthesized. The oligonucleotide sequences are shown in Table 3. Target sites are indicated by nucleotide numbers to which the oligonucleotide binds. The human Survivin mRNA was generated by splicing nucleotides 2811-2921, 3174-3283, 5158-5275 and 11955-12044 from Genbank accession no. U75285 creating the complete human mRNA sequence herein incorporated as SEQ ID NO: 97.

All compounds in Table 3 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines.

Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, "N.D." indicates "no data".

Table 3

Inhibition of human Survivin mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

	ISIS #	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO
5	107289	Coding	14	gccaacgggtcccgcgat	5	98
	107290	Coding	35	catgccgccgccgccacc	4	99
	107291	Coding	90	agatgcggtggctccttga	94	100
	107292	Coding	110	gggccagttcttgaatgt	14	101
10	107293	Coding	166	tggatgaagccagcctcg	0	102
	107294	Coding	212	gcagaagaaacactgggc	0	103
	107295	Coding	233	ccagccttccagctcctt	0	104
	107296	Coding	283	caaccggacgaatgcttt	0	105
	107297	Coding	299	gacagaaaggaaagcgca	83	106
15	107298	Coding	313	tcaaactgcttcttgaca	73	107
	107299	Coding	329	accaaggggttaattcttc	0	108
	107300	Coding	359	ggctctttctctgtccag	7	109
	107301	Coding	370	atthttgttcttggtctt	4	110
	107302	Coding	398	tttcttcttattgttgg	11	111
20	107303	Coding	412	gtttcctcaaattctttc	0	112
	107304	Coding	421	ttcttcgcagtttcctca	49	113
	107305	Coding	432	cacggcgcactttcttcg	22	114
	107306	Coding	445	agctgctcgatggcacgg	7	115
	107307	Coding	495	ccactctgggaccaggca	0	116
25	107308	Coding	514	aaccctggaagtgggtgca	0	117
	107309	Coding	529	tggcaccagggaataaac	0	118
	107310	Coding	566	tcctaagacattgctaag	1	119
	107311	Coding	579	tgttgatctcctttccta	3	120
	107312	Coding	590	taatttgaaaatgttgat	15	121
30	107313	Coding	599	tgaaacatctaatttgaa	0	122
	107314	Coding	613	aacaggagcacagttgaa	27	123
	107315	Coding	619	agacaaaacaggagcaca	0	124
	107316	Coding	630	tgccactttcaagacaaa	24	125
	107317	Coding	635	tctggtgccactttcaag	0	126
35	107318	Coding	653	tgcacaggcagaagcacc	15	127
	107319	Coding	676	ccactgttaccagcagca	4	128
	107320	Coding	701	aaaagagagagagagaga	0	129
	107321	Coding	766	cttcttcctccctcactt	7	130
	107322	Coding	789	agctctagcaaaaggac	0	131
40	107323	Coding	814	ctctgcccacgcgaacaa	13	132

	107324	Coding	836	cagacacattcactgtgg	0	133
	107325	Coding	852	tcaacaacatgaggtcca	0	134
	107326	Coding	882	gccaaagtccacactcagg	0	135
	107327	Coding	1039	gaggagccagggactctg	16	136
5	107328	Coding	1067	aataagaaagccatggtg	0	137
	107329	Coding	1080	acaattcaaacaaaataa	30	138
	107330	Coding	1081	aacaattcaaacaaaata	0	139
	107331	Coding	1082	taacaattcaaacaaaat	3	140
	107332	Coding	1083	ttaacaattcaaacaaaa	31	141
10	107333	Coding	1084	attaacaattcaaacaaa	9	142
	107334	Coding	1085	aattaacaattcaaacaa	10	143
	107335	Coding	1092	ttctgtgaattaacaatt	16	144
	107336	Coding	1093	attctgtgaattaacaat	0	145
	107337	Coding	1094	tattctgtgaattaacaa	25	146
15	107338	Coding	1095	ctattctgtgaattaaca	12	147
	107339	Coding	1096	gctattctgtgaattaac	14	148
	107340	Coding	1097	tgctattctgtgaattaa	14	149
	107341	Coding	1098	gtgctattctgtgaatta	8	150
	107342	Coding	1100	ttgtgctattctgtgaat	18	151
20	107343	Coding	1101	tttgtgctattctgtgaa	33	152
	107344	Coding	1102	gtttgtgctattctgtga	11	153
	107345	Coding	1103	agtttgtgctattctgtg	21	154
	107346	Coding	1104	tagtttgtgctattctgt	17	155
	107347	Coding	1105	gtagtttgtgctattctg	57	156
25	107348	Coding	1106	tgtagtttgtgctattct	6	157
	107349	Coding	1107	ttgtagtttgtgctattc	13	158
	107350	Coding	1108	attgtagtttgtgctatt	15	159
	107351	Coding	1109	aattgtagtttgtgctat	0	160
	107352	Coding	1110	taattgtagtttgtgcta	25	161
30	107353	Coding	1120	tgcttagttttaattgta	0	162
	107354	Coding	1144	ccccaatgacttagaatg	7	163
	107355	Coding	1163	cctgaagttcaccccggt	19	164
	107356	Coding	1184	tctattctgtctcctcat	0	165
	107357	Coding	1199	gacgcttcctatcactct	18	166
35	107358	Coding	1222	agtggcaaaaggagtatc	0	167
	107359	Coding	1239	ctgtctaatacacacagca	0	168
	107360	Coding	1281	tgaggaggagcgccag	0	169
	107361	Coding	1350	gcagcccagccagtcccc	0	170
	107362	Coding	1379	aggttgggctgacagaca	1	171
40	107363	Coding	1399	ggagaacgtgacagatgt	23	172
	107364	Coding	1425	ggcgaggactgctctctc	0	173
	107365	Coding	1470	cttcagccctgcgggagc	0	174
	107366	Coding	1488	ccatcatcttacgccaga	0	175

107367	Coding	1509	agggaggagggcgcaatca	0	176
107368	Coding	1585	atttctcaggaacagccg	7	177

As shown in Table 3, SEQ ID Nos 101, 106, 107, 113, 138, 141, 152 and 156 demonstrated at least 30% inhibition of human Survivin expression in this assay and are therefore preferred.

Example 18

Antisense inhibition of mouse Survivin expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the mouse Survivin RNA, using published sequences (GenBank accession number AB013819, incorporated herein as SEQ ID NO: 10). The oligonucleotides are shown in Table 4. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 4 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse Survivin mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 4

Inhibition of mouse Survivin mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

	ISIS #	REGION	TARGET SITE	SEQUENCE	% INHIBITION	SEQ ID NO
5	114968	5'UTR	3	agagccccggccccctcgtg	0	178
	114967	5'UTR	4	gagagccccggccccctcgt	0	179
	114966	5'UTR	16	agagcatgccgggagagccc	0	108
	114965	5'UTR	25	gcgcgccgcagagcatgccg	0	181
10	114964	5'UTR	55	aaacgcaggattcaaatacgc	0	182
	114963	5'UTR	66	caagacgactcaaacgcagg	0	183
	114962	5'UTR	68	gccaagacgactcaaacgca	0	184
	114961	Start Codon	92	catgatggcgtcaccacaac	0	185
	114972	Start Codon	101	cggagctcccatgatggcgt	27	186
15	114960	Start Codon	104	cgccggagctcccatgatgg	47	187
	114959	Coding	171	ggaagggccagttcttgaag	35	188
	114958	Coding	184	gcgcagtcctccaggaaggg	0	189
	114957	Coding	186	aggcgcagtcctccaggaag	10	190
	114957	Coding	186	aggcgcagtcctccaggaag	6	191
20	114971	Coding	189	tgcaggcgcagtcctccagg	30	192
	114956	Coding	249	aatcaggctcgttctcggtta	46	193
	114955	Coding	259	cactggggccaaatcaggctc	14	194
	114954	Coding	289	cagccttccaattccttaaa	0	195
	114953	Coding	300	catcggttcccagccttcc	67	196
25	114952	Coding	303	tgatcatcggttcccagcct	83	197
	114951	Coding	315	cctctatcggttgtcatcg	40	198
	114950	Coding	327	gctttctatgctcctctatc	39	199
	114949	Coding	358	ttgacagtgaggaaggcgca	0	200
	114948	Coding	374	ttcttccatctgcttcttga	0	201
30	114947	Coding	387	cactgacggttagttcttcc	39	202
	114946	Coding	389	ttcactgacggttagttctt	12	203
	114945	Coding	394	aagaattcactgacggttag	26	204
	114944	Coding	396	tcaagaattcactgacggtt	38	205
	114943	Coding	465	cttcaaactctttttgcttg	10	206
35	114942	Coding	497	ctcaattgactgacgggttag	48	207
	114941	Coding	498	gctcaattgactgacgggtta	39	208
	114940	Coding	499	tgctcaattgactgacgggt	23	219

5	ISIS #	REGION	TARGET SITE	SEQUENCE	% INHIBITION	SEQ ID NO
	114939	Stop	521	ggctcagcattaggcagcca	18	210
	114938	Stop Codon	531	tctcagcaaaggctcagcat	42	211
	114937	3'UTR	601	gctaggaggccctggctgga	52	212
	114936	3'UTR	613	ctctaagatcctgctaggag	39	213
5	114935	3'UTR	627	accactgtctccttctctaa	35	214
	114934	3'UTR	642	atccagtttcaaaataccac	0	215
	114933	3'UTR	649	at ttgatatccagtttcaaa	20	216
	114932	3'UTR	666	aaagcaaaacaaaaaatatt	7	217
	114931	3'UTR	683	agagaggtagccactttaa	45	218
10	114930	3'UTR	688	accaaagagaggtagccact	44	219
	114929	3'UTR	713	cgtcacaatagagcaaagcc	14	220
	114970	3'UTR	721	taagtccacgtcacaataga	7	221
	114928	3'UTR	741	ttcatcacttccttattgct	8	222
	114927	3'UTR	756	agagaacactgtcccttcat	15	223
15	114969	3'UTR	786	acaggcacccccgacccccac	4	224
	114926	3'UTR	801	gaaccaagaccttgacaggg	59	225
	114925	3'UTR	812	tatcacaatcagaaccaaga	34	226
	114924	3'UTR	834	cattagcagccctgtatgga	18	227
	114923	3'UTR	856	aaccacacttacccatgggc	52	228
20	114922	3'UTR	903	gtggtaggaaaactcatcag	64	229
	114921	3'UTR	934	actttttcaagtgattttat	13	230

As shown in Table 4, SEQ ID NOs 187, 188, 192, 193, 196, 197, 198, 199, 202, 205, 207, 208, 211, 212, 213, 214, 218, 219, 225, 226, 228 and 229 demonstrated at least 30% inhibition of mouse Survivin expression in this experiment and are therefore preferred.

In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse Survivin RNA, using published sequences (GenBank accession number AA717921, incorporated herein as SEQ ID NO: 231). The oligonucleotides are shown in Table 5. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide

binds. All compounds in Table 5 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' 5 directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were 10 analyzed for their effect on mouse Survivin mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 5

15 Inhibition of mouse Survivin mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SITE	SEQUENCE	% INHIBITION	SEQ ID NO
114920	5'UTR	2	aatcccagccaaggatccga	0	232
20 114919	5'UTR	21	cgtggtggctcacaccttta	1	233
114918	5'UTR	33	tttcaagccgggcgtggtgg	11	234
114917	5'UTR	57	acatatatatataaacat	0	235
114916	5'UTR	87	aattttccttccttgatttt	5	236
114915	5'UTR	105	tactgagctacaaactggaa	41	237
25 114914	5'UTR	108	acttactgagctacaaactg	0	238
114913	5'UTR	168	aagttattatTTTTgtattg	0	239
114912	5'UTR	169	aaagttattatTTTTgtatt	7	240
114911	5'UTR	184	taaatcattaaaaggaaagt	0	241
114910	5'UTR	197	catcgtggcaagataaatca	0	242
30 114909	5'UTR	229	gcctgtccagggtgagatgc	0	243
114908	5'UTR	231	ttgcctgtccagggtgagat	0	244
114907	5'UTR	240	gggccaggcttgccgtgcca	13	245
114906	Start Codon	293	ggtctcctttgcctggaatg	23	246
114905	Start Codon	296	gttggtctcctttgcctgga	59	247

As shown in Table 5, SEQ ID NOS 237 and 247 demonstrated at least 30% inhibition of mouse Survivin expression in this experiment and are therefore preferred.

Example 19

5 Western blot analysis of Survivin protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 hours after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 μ l/well), boiled for 5
10 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Survivin is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody
15 species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

Example 20

Effect of antisense inhibition of Survivin on apoptosis

ISIS 23722 and a mismatch control, ISIS 28598
20 (TAAGCTGTTCTATGTGTT; SEQ ID NO: 248) were assayed for their effect on apoptosis in HeLa cells. The caspase inhibitor z-VAD.fmk was purchased from Calbiochem (La Jolla CA) and used according to manufacturer's recommendations. In HeLa cells without oligonucleotide, approximately 4% of cells are
25 hypodiploid (indicating DNA fragmentation, a measure of apoptosis). With the addition of ISIS 23722, approximately 22% of cells are hypodiploid, compared to approximately 11% with the mismatch oligonucleotide. In the presence of the caspase inhibitor z-VAD.fmk (42.8 mM), the percent of hypodiploid
30 (apoptotic) cells drops to 3% without oligonucleotide, 6% with ISIS 23722 and 4% with the mismatch control. This demonstrates

that antisense inhibition of Survivin increases apoptosis and that this effect is caspase-mediated.

Example 21

Effect of antisense inhibition of Survivin on cytokinesis

5 HeLa cells treated with an antisense oligonucleotide targeted to Survivin (ISIS 23722) can be observed to form large, multinucleated cells as a result of improper cell division. The mismatch control oligonucleotide did not have this effect and cells appeared normal (comparable to untreated
10 controls).

This effect can be quantitated by flow cytometry.

Untreated cells or cells treated with the control oligonucleotide display two prominent peaks, representing populations of cells in the G1 phase and the G2/M phase of
15 cell division, respectively. G1 cells have a single copy of their DNA (1x) and G2/M cells have two copies (2x). Over time from 24 hours to 72 hours, these 1x and 2x peaks remain virtually unchanged in cells treated with the control oligonucleotide or without oligonucleotide. However, in cells
20 treated with the antisense oligonucleotide targeted to Survivin, the majority of cells have two copies of DNA by 24 hours after oligo treatment. This indicates that cell division is arrested. By 48 hours after treatment with this oligonucleotide, a 4x peak is approximately equal in size to
25 the 1x and 2x peaks, indicating roughly equal numbers of cells with one, two and four copies of DNA. By 72 hours the largest peak is 16x, indicating that cells have 16 copies of their DNA and thus that division of the cytoplasm has not occurred for multiple generations. Thus inhibition of Survivin is shown to
30 interfere with cytokinesis.

Example 22**Effect of antisense inhibition of Survivin on cell proliferation**

Human HT1080 fibrosarcoma cells (American Type Culture
5 Collection, CCL-121) were grown in minimal essential medium
with 1% non-essential amino acids, 90% with 10% fetal bovine
serum (Gibco BRL). Cells were electroporated (Electro Square
Porator, Model T820, Biotechnologies and Experimental
Research, BTX) with oligonucleotide at settings of 225 volts
10 for 6 milliseconds with a single pulse and oligonucleotide
concentrations of 1 to 30 μ M. ISIS 23722 (SEQ ID NO: 87) and
the mismatch control ISIS 28598 (SEQ ID NO: 248) were used.
Cells were plated at 1500 cells/well immediately after
electroporation and viable cells were measured by MTT assay
15 at 24, 48, 72, 96 and 120 hours after electroporation. Growth
rate (Δ OD/hour) was plotted against oligonucleotide
concentration. At an oligonucleotide concentration of 1 μ M,
growth rates were virtually identical for ISIS 23722 and the
control, ISIS 28598 (0.01726 and 0.01683, respectively. At 5
20 μ M oligonucleotide, the growth rate of the ISIS 23722-treated
cells was 16.7% less than the control treated cells (0.01433
vs. 0.01728 Δ OD/hour, respectively). At 10 μ M the growth rate
of the ISIS 23722-treated cells was 45% less than the control
treated cells (0.009677 vs. 0.01762 Δ OD/hour, respectively).
25 At 20 μ M the growth rate of the ISIS 23722-treated cells was
52% less than the control treated cells (0.007716 vs. 0.01620
 Δ OD/hour, respectively). At 30 μ M the growth rate of the ISIS
23722-treated cells was 54% less than the control treated
cells (0.006562 vs. 0.01417 Δ OD/hour, respectively). Thus
30 treatment with antisense oligonucleotide targeted to Survivin
was demonstrated to reduce the rate of tumor cell
proliferation by over 50%.

In an similar experiment using a different control
oligonucleotide, a 20mer random oligonucleotide (ISIS 29848,
35 SEQ ID NO: 249; NNNNNNNNNNNNNNNNNNNNNN, wherein each N is a

mixture of A, C, G and T) a similar result was obtained. Oligonucleotides were tested at concentrations of 0.5 to 20 μM , and cell viability was again measured by MTT assay and growth rate ($\Delta\text{OD}/\text{hour}$) was calculated. At 0.5 μM oligonucleotide concentrations, growth rates were similar for ISIS 23722 and control treated cells (0.01441 and 0.01342, respectively). At 10 μM the growth rate of the ISIS 23722-treated cells was 57% less than the control treated cells (0.005568 vs. 0.01298 $\Delta\text{OD}/\text{hour}$, respectively). At 20 μM the growth rate of the ISIS 23722-treated cells was 77% less than the control treated cells (0.002433 vs. 0.01073 $\Delta\text{OD}/\text{hour}$, respectively). Thus treatment with antisense oligonucleotide targeted to Survivin was demonstrated to reduce the rate of tumor cell proliferation by over 75% compared to control.

A similar experiment was conducted in human MCF-7 breast carcinoma cells, testing ISIS 23722 and the random control ISIS 29848 at doses from 0.5 to 20 μM . Cells were electroporated (Electro Square Porator, Model T820 manufactured by Biotechnologies and Experimental Research, BTX) at settings of 175 volts for 6 milliseconds with a single pulse with oligonucleotide and growth rates were calculated as described above. At 0.5 μM oligonucleotide concentrations, growth rates were similar for ISIS 23722 and control treated cells (0.005959 and 0.005720, respectively). At 1 μM oligonucleotide, growth rates were still relatively similar for ISIS 23722 and control treated cells (0.005938 and 0.005479, respectively). At 5 μM oligonucleotide, growth rates were 0.002574 and 0.005676, respectively for ISIS 23722 and control treated cells. At 10 μM the growth rate of the ISIS 23722-treated cells was 69% less than the control treated cells (0.001828 vs. 0.005901 $\Delta\text{OD}/\text{hour}$, respectively). At 20 μM the growth rate of the ISIS 23722-treated cells was 64% less than the control treated cells (0.001523 vs. 0.004223 $\Delta\text{OD}/\text{hour}$, respectively). Thus treatment with antisense oligonucleotide targeted to Survivin was demonstrated to

significantly reduce the rate of tumor cell proliferation in several tumor cell types.

Example 23

Sensitization of cells to chemotherapeutic agent stimuli by

5 ISIS 23722

ISIS 23722 (SEQ ID NO: 87) and a control oligonucleotide, ISIS 29848, a 20mer random oligonucleotide (ISIS 29848, SEQ ID NO: 249; NNNNNNNNNNNNNNNNNNNNNN, wherein each N is a mixture of A, C, G and T) were assayed for their ability to sensitize
10 cells to the effects of the chemotherapeutic agents, Taxol and Cisplatin.

Human HT1080 fibrosarcoma cells (American Type Culture Collection, CCL-121) were grown in minimal essential medium with 1% non-essential amino acids, 90% with 10% fetal bovine
15 serum (Gibco BRL). Cells were treated with oligonucleotide at concentrations of 10 to 100 nM alone or in combination with Taxol (concentrations of 0.25 nM or 1nM) or Cisplatin (concentrations of 5 μ M or 25 μ M). Treatment with Taxol or Cisplatin followed oligonucleotide treatment by 1-2 hr. Cells
20 were plated at 1500 cells/well immediately after treatment and viable cells were measured by MTT assay at 12, 24, 36, 48, and 60 hours after treatment. Growth rate (Δ OD/hour) is plotted against oligonucleotide and/or chemotherapeutic agent concentration.

25 A similar experiment was conducted in human MCF-7 breast carcinoma cells (American Type Culture Collection), testing ISIS 23722 and the random control ISIS 29848 at doses from 10 to 100 nM alone or in combination with Taxol (concentrations of 0.5 nM or 2nM) or Cisplatin (concentrations of 2.5 μ M or
30 15 μ M). Cells were grown in Dulbecco's Modified Eagles medium (low glucose), 90% with 10% fetal bovine serum (Gibco BRL). Treatment with Taxol or Cisplatin followed oligonucleotide treatment by 1-2 hr. Cells were plated at 2500 cells/well immediately after transfection and viable cells were measured

by MTT assay at 12, 24, 36, 48, and 60 hours after treatment. Growth rate (Δ OD/hour) is plotted against oligonucleotide and/or chemotherapeutic agent concentration.

Example 24

5 Mixed backbone version of active oligonucleotide ISIS 23722

An oligonucleotide having the same sequence as ISIS 23722 (SEQ ID NO:87) was synthesized, this time as a 2' MOE gapmer with phosphodiester backbone linkages in the 2'MOE "wings" and phosphorothioate linkages in the 2'deoxy "gap". Both
10 cytosines are 5-methylcytosines.

This compound is tested for its effects on cell proliferation, cytokinesis and sensitization to chemotherapeutic agents as described herein in previous examples.

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human Survivin, wherein said antisense compound inhibits the expression of human Survivin.
- 5 2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 comprising at
10 least an 8-nucleobase portion of SEQ ID NO: 19, 21, 23, 24, 25, 27, 29, 30, 32, 37, 40, 41, 43, 48, 49, 50, 51, 52, 56, 60, 65, 68, 70, 72, 76, 80, 83, 87, 88, 91, 92, 101, 106, 107, 113, 138, 141, 152 or 156.
4. The antisense compound of claim 3 comprising SEQ
15 ID NO: 25, 30, 40, 43, 48, 65, 70, 80, 83 or 88.
5. The antisense compound of claim 2 which comprises at least one modified internucleoside linkage.
6. The antisense compound of claim 5 wherein the
20 modified internucleoside linkage is a phosphorothioate linkage.
7. The antisense compound of claim 2 which comprises at least one modified sugar moiety.
8. The antisense compound of claim 7 wherein the
25 modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2 which comprises at least one modified nucleobase.

10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. The antisense compound of claim 2 which is a chimeric oligonucleotide.

12. A composition comprising the antisense compound of
5 claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

10 15. A method of inhibiting the expression of Survivin in human cells or tissues comprising contacting human cells or tissues with the antisense compound of claim 1 so that expression of Survivin is inhibited.

15 16. A method of treating an animal having a disease or condition associated with Survivin comprising administering to an animal having a disease or condition associated with Survivin a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of Survivin is inhibited.

20 17. The method of claim 16 wherein the disease or condition is a hyperproliferative condition.

18. The method of claim 17 wherein the hyperproliferative condition is cancer.

25 19. A method of treating a human having a disease or condition characterized by a reduction in apoptosis comprising

administering to a human having a disease or condition characterized by a reduction in apoptosis a prophylactically or therapeutically effective amount of the antisense compound of claim 1.

20. A method of modulating apoptosis in a cell
5 comprising contacting a cell with the antisense compound of claim 1 so that apoptosis is modulated.

21. A method of modulating cytokinesis in a cell comprising contacting a cell with the antisense compound of claim 1 so that cytokinesis is modulated.

10 22. A method of modulating the cell cycle in a cell comprising contacting a cell with the antisense compound of claim 1 so that the cell cycle is modulated.

23. A method of inhibiting the proliferation of cells comprising contacting cells with an effective amount of the
15 antisense compound of claim 1, so that proliferation of the cells is inhibited.

24. The method of claim 23 wherein said cells are cancer cells.

20 25. The composition of claim 12 further comprising a chemotherapeutic agent.

26. The method of claim 19 further comprising administering to the patient a chemotherapeutic agent.

27. The method of claim 20 wherein said modulation of
25 apoptosis is sensitization to an apoptotic stimulus.

28. The method of claim 27 wherein said apoptotic stimulus is a cytotoxic chemotherapeutic agent.

29. The method of claim 23 further comprising contacting said cells with a chemotherapeutic agent.

30. The method of claim 29 wherein said
5 chemotherapeutic agent is taxol or cisplatin.

SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.
C. Frank Bennett
Elizabeth J. Ackermann
Eric E. Swayze
Lex M. Cowser

<120> ANTISENSE MODULATION OF SURVIVIN EXPRESSION

<130> ISPH-0536

<150> 09/496,694
<151> 2000-02-02

<150> 09/286,407
<151> 1999-04-05

<150> 09/163,162
<151> 1998-09-29

<160> 249

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 1
tccgtcatcg ctctcaggg 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 2
atgcattctg cccccaagga 20

<210> 3
<211> 14796
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (2811)...(2921)
<220>
<221> CDS
<222> (3174)...(3283)
<220>
<221> CDS
<222> (5158)...(5275)
<220>
<221> CDS
<222> (11955)...(12044)

<400> 3
tctagacatg cggatatatt caagctgggc acagcacagc agccccaccc caggcagctt 60
gaaatcagag ctgggggtcca aagggaaccac accccgaggg actgtgtggg ggtcggggca 120
cacaggccac tgcttcccc cgtctttctc agccattcct gaagtcagcc tcactctgct 180

WO 01/57059

PCT/US01/02939

tctcagggat	ttcaaatgtg	cagagactct	ggcacttttg	tagaagcccc	ttctggctct	240
aacttacacc	tggatgctgt	ggggctgcag	ctgctgctcg	ggctcgggag	gatgctgggg	300
gcccgggtgcc	catgagcttt	tgaagctcct	ggaactcggt	tttgaggggtg	ttcaggtcca	360
ggtggacacc	tgggctgtcc	ttgtccatgc	atltgatgac	attgtgtgca	gaagtgaaaa	420
ggagttaggc	cgggcatgct	ggcttatgcc	tgtaatccca	gcactttggg	aggctgaggc	480
gggtggatca	cgaggtcagg	agttcaatac	cagcctggcc	aagatggtga	aaccccgctc	540
ctactaaaaa	tacaaaaaaa	ttagccgggc	atggtggcgg	gcgcatgtaa	tcccagctac	600
tgggggggct	gaggcagaga	attgctggaa	cccaggagat	ggaggttgca	gtgagccaag	660
attgtgcac	tgcactgcac	tccagcctgg	cgacagagca	agactctgtc	tcaaaaaaaa	720
aaaaaaaag	tgaaggag	ttgttccttt	cctccctcct	gagggcaggc	aactgctgcg	780
gttgccagtg	gaggtgggtgc	gtccttggtc	tgtgcctggg	ggccacccca	gcagaggcca	840
tgggtgggtgcc	agggcccggt	tagcgagcca	atcagcagga	cccaggggag	acctgccaaa	900
gtcaactgga	tttgataact	gcagcgaagt	taagtctcct	gattttgatg	attgtgttgt	960
ggttgtgtaa	gagaatgaag	tatttcgggg	tagtatggta	atgccttcaa	cttacaacg	1020
gttcaggtaa	accacccata	tacatacata	tacatgcatg	tgatatatac	acatacaggg	1080
atgtgtgtgt	gttcacatat	atgaggggag	agagactagg	ggagagaaag	taggttgggg	1140
agagggagag	agaaaggaaa	acaggagaga	agagagagc	ggggagtaga	gagagggaaag	1200
gggtaagaga	gggagaggag	gagagaaagg	gaggaagaag	cagagagtga	atgttaaagg	1260
aaacaggcaa	aacataaaca	gaaaatctgg	gtgaagggtg	tatgagtatt	ctttgtacta	1320
ttcttgcaat	tatcttttat	ttaaattgac	atcgggcccgg	gcgcagtggc	tcacatctgt	1380
aatcccagca	ctttggggagg	ccgaggcagg	cagatcaact	gaggtcagga	gtttgagacc	1440
agcctggcaa	acatggtgaa	accccatctc	tactaaaaat	acaaaaatta	gcctgggtgtg	1500
gtgggtgcag	cctttaatct	cagctactcg	ggaggtgag	gcaggagaat	cgcttgaaac	1560
cgtggcgggg	aggaggttgc	agtgaactga	gatcatgcc	ctgcactcca	gcctgggcga	1620
tagagcgaga	ctcagtttca	aataaataaa	taaacatcaa	aataaaaaag	tactgtatta	1680
aagaatgggg	gcggggtggg	aggggtgggg	agaggttgca	aaaaataaata	aataaataaa	1740
taaaccccaa	aatgaaaaag	acagtggagg	caccaggcct	gcgtggggct	ggagggctaa	1800
taaggccagg	cctcttatct	ctggccatag	aaccagagaa	gtgagtggat	gtgatggcca	1860
gctccagaag	tgactccaga	acaccctgtt	ccaaagcaga	ggacacactg	attttttttt	1920
taataggctg	caggacttac	tgttggtggg	acgcctgct	ttgcgaaggg	aaaggaggag	1980
tttgccctga	gcacaggccc	ccaccctcca	ctgggctttc	cccagctccc	ttgtcttct	2040
atcaccgtag	tggcccagtc	cctggcccct	gactccagaa	ggtggcccct	ctggaaaccc	2100
aggctcgtgca	gtcaacgatg	tactcgccgg	gacagcgatg	tctgctgcac	tccatccctc	2160
ccctgttcat	ttgtccttca	tgcccgctcg	gagtagatgc	tttttgaga	ggtggcacc	2220
tgtaaaactc	tcctgtctga	cttttttttt	tttttttagac	tgagttttgc	tctgtgtgcc	2280
taggctggag	tgcaatggca	caatctcagc	tcactgcacc	ctctgcctcc	cgggttcaag	2340
cgattctcct	gcctcagcct	cccagtagt	tgggattaca	ggcatgcacc	accacgccca	2400
gctaattttt	gtattttttag	tagagacaag	gtttcacctg	gatggccagg	ctggtcttga	2460
actccaggag	tcaagtgatg	ctcctgccta	ggcctctcaa	agtgttggga	ttacaggcgt	2520
gagccactgc	acccggcctg	cacgcgttct	ttgaaagcag	tcgagggggc	gctaggtgtg	2580
ggcagggagc	agctggcgcg	gcgtcgctgg	gtgcaccgag	accacgggca	gagccacgag	2640
gcggggaggac	tacaactccc	ggcacacccc	gcgcgcggcc	gcctctactc	ccagaaggcc	2700
gcgggggggtg	gaccgcctaa	gagggcgctg	gtccccgaca	tgccccgcgg	cgcgccatta	2760
accgccagat	ttgaatcgcg	ggaccgcgtt	gcagaggtgg	cggcggcggc	atg ggt	2816

Met Gly

1

gcc	ccg	acg	ttg	ccc	cct	gcc	tgg	cag	ccc	ttt	ctc	aag	gac	cac	cgc	2864
Ala	Pro	Thr	Leu	Pro	Pro	Ala	Trp	Gln	Pro	Phe	Leu	Lys	Asp	His	Arg	
		5					10					15				

atc	tct	aca	ttc	aag	aac	tgg	ccc	ttc	ttg	gag	ggc	tgc	gcc	tgc	acc	2912
Ile	Ser	Thr	Phe	Lys	Asn	Trp	Pro	Phe	Leu	Glu	Gly	Cys	Ala	Cys	Thr	
	20					25					30					

ccg	gag	cgg	gtgagactgc	ccggcctcct	gggggtcccc	acgcccgcct	tgccctgtcc	2971
Pro	Glu	Arg						
	35							

ctagcgaggc	cactgtgact	gggcctcggg	ggtacaagcc	gccctcccct	ccccgtcctg	3031
tcccagcgga	ggccactgtg	gctggggcccc	ttgggtccag	gccggcctcc	cctccctgct	3091
ttgtcccat	cgaggccttt	gtggctgggc	ctcgggggtt	cgggctgcca	cgtccactca	3151
cgagctgtgc	tgtcccttgc	ag atg gcc	gag gct ggc	ttc atc cac	tgc ccc	3203
		Met Ala	Glu Ala Gly	Phe Ile His	Cys Pro	
		40		45		

act gag aac gag cca gac ttg gcc cag tgt ttc ttc tgc ttc aag gag 3251
 Thr Glu Asn Glu Pro Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu
 50 55 60

ctg gaa ggc tgg gag cca gat gac gac ccc at gtaagtcttc tctggccagc 3303
 Leu Glu Gly Trp Glu Pro Asp Asp Pro Ile
 65 70

ctcgatgggc tttgttttga actgagttgt caaaagattt gagttgcaaa gacacttagt 3363
 atgggaggggt tgctttccac cctcattgct tcttaaacag ctgttgtaga cggatacctc 3423
 tctatatgct ggtgccttgg tgatgcttac aacctaatat aatctcattt gacccaaatg 3483
 ccttggggtg gacgtaagat gcctgatgcc tttcatgttc aacagaatac atcagcagac 3543
 cctgttggtg tgaactccca ggaatgtcca agtgcttttt ttgagatttt ttaaaaaaca 3603
 gttaattga aatataacct acacagcaca aaaattaccc ttgaaagtg tgcacttcac 3663
 actttcggag gctgaggcgg gcggatcacc agttcaagac ctgcctggcc 3723
 aacttggcga aaccccgctc ctactaaaaa tacaaaaatt agccgggcat ggtagcgcac 3783
 gcccgtaatc ccagctactc gggaggctaa ggaggagaa tcgcttgaac ctgggaggcg 3843
 gaggttgtag tgagccgaga ttgtgccaat gcaactccagc ctccggcgaca gagcgagact 3903
 ccgtcataaa aataaaaaat tgaaaaaaa aaaagaaaga aagcatatac ttcagtgttg 3963
 ttctggattt ttttcttcaa gatgcctagt taatgacaat gaaattctgt actcggatgg 4023
 tatctgtctt tccacactgt aatgccatat tcttttctca cctttttttc tgtcggattc 4083
 agttgcttcc acagctttaa tttttttccc ctggagaatc accccagttg tttttctttt 4143
 tggccagaag agagttagctg tttttttct tagtatgtt gctatgggtg ttatactgca 4203
 tccccgtaat cactgggaaa agatcagtggt tattcttctt gaaaatgaat aagtgttatg 4263
 atattttcag attagagtta caactggctg tcttttttga ctttgtgtgg ccattgtttc 4323
 attgtaatgc agttctggta acggtgtag tcagttatac agggagactc cccttctctg 4383
 aaatgagagt gtgagctagg gggctccttg ggggaacccg ggcaataatg cccttctctg 4443
 cccttaatcc ttacagtggg ccgggcacgg tggcttacgc ctgtaatacc agcacttttg 4503
 gagggccagg cgggcccagc acgaggtcag gagatcgaga ccattcttgg taatacggtg 4563
 aaaccccgct tccactaaaa atacaaaaaa tttagccggc gtgggtgggtg gcgcctgtag 4623
 tcccagctac tcgggaggtc gaggcaggag aatggcgtga acccaggagg cggagcttgc 4683
 agtgagccga gattgcacca ctgcactcca gcctgggcga cagaatgaga ctccgtctca 4743
 aaaaaaaaaa aaaaagaaaa aaatctttac agtggattac ataacaattc cagtgaatg 4803
 aaattacttc aaacagtctc ttgagaatgt tggagggtat tgacatgtaa ttccttttga 4863
 catataccat gtaacacttt tccaactaat tgctaaggaa gtccagataa aatagatata 4923
 ttagccacac agatgtgggg ggagatgtcc acagggagag agaagtgct aagagtgcc 4983
 atatgggaat gtggcttggg caaagcactg atgccatcaa cttcagactt gacgtcttac 5043
 tectgaggca gagcagggtg tgctgttggg gggcgtgggg aggtggcccg tggggagtg 5103
 actgccgctt taatcccttc agctgccttt ccgctgttgt tttgattttt ctag a gag 5161
 Glu
 75

gaa cat aaa aag cat tgc tcc ggt tgc gct ttc ctt tct gtc aag aag 5209
 Glu His Lys Lys His Ser Ser Gly Cys Ala Phe Leu Ser Val Lys Lys
 80 85 90

cag ttt gaa gaa tta acc ctt ggt gaa ttt ttg aaa ctg gac aga gaa 5257
 Gln Phe Glu Glu Leu Thr Leu Gly Glu Phe Leu Lys Leu Asp Arg Glu
 95 100 105

aga gcc aag aac aaa att gtatgtattg ggaataagaa ctgctcaaac cctgttcaat 5315
 Arg Ala Lys Asn Lys Ile
 110

gtcttttagca ctaaactacc tagtccctca aagggactct gtgttttctc caggaagcat 5375
 tttttttttt tttctgagat agagtttcac tcttggtgcc caggctggag tgcaatgggtg 5435
 caatcttggc tcaactgcaac ctctgcctct cgggttcaag tgattctcct gcctcagcct 5495
 cccaagtaac tgggattaca gggagagtgc accacaccca gctaattttt gtatttttag 5555
 tagagatggg gtttcaccac attgcccagg ctggcttga actcctgacc tctgtattcg 5615
 cccaccttgg cctcccaaag tgctgggatt acagggcgtga accaccacgc ctggcttttt 5675
 tttttttgtt ctgagacaca gtttcaactct gttacccagg ctggagtagg gtggcctgat 5735
 ctggatcac tgcaacctcc gcctcctggg ctcaagtgtat ttgcctgctt cagcctccca 5795
 agtagccgag attacaggca tgtgccacca caccaggta atttttgtat ttttggtaga 5855
 gacgaggttt caccatgttg gccaggctgg ttttgaactc ctgacctcag gtgatccacc 5915
 cgccctcagcc tcccaaagtg ctgagattat aggtgtgagc caccacacct ggcctcagga 5975

agtattttta	tttttaaatt	tatttatatta	tttgagatgg	agtcttgctc	tgtcgccag	6035
gctagagtgc	agcgacggga	tctcggctca	ctgcaagctc	cgccccccag	gttcaagcca	6095
ttctcctgcc	tcagcctccc	gagtagctgg	gactacaggc	gccccgccacc	acaccggct	6155
aatttttttg	tatttttagt	agagacgggt	tttcaccgtg	ttagccagga	gggtcttgat	6215
ctcctgacct	cgtgatctgc	ctgcctcggc	ctcccaaagt	gctgggatta	cagggtgag	6275
ccaccacacc	cggctatttt	tatttttttg	agacaggga	tcactctgtc	acctgggctg	6335
cagtgcagtg	gtacaccata	gctcactgca	gcctcgaact	cctgagctca	agtgatccctc	6395
ccacctcatc	ctcacaagta	attgggacta	caggtgcacc	ccaccatgcc	cacctaat	6455
atttatattat	ttatttat	attttcatag	agatgagggt	tcctctgtgt	gtccaggctg	6515
gtcttgaact	cctgagctca	cgggatccct	ttgcctgggc	ctcccaaagt	gctgagatta	6575
caggcatgag	ccaccgtgcc	cagctaggaa	tcatttttaa	agccctagg	atgtctgtgt	6635
gatttttaaag	ctcctggagt	gtggccggta	taagtatata	ccggtataag	taaataccac	6695
attttgtctg	agtatttact	agaaacttag	tcatttatct	gaagttgaaa	tgttaacggg	6755
ctttatttat	ttatttat	atttat	ttttaatttt	tttttttgag	acgagtctca	6815
ctttgtcacc	caggctggag	tgcagtggca	cgatctcggc	tcactgcaac	ctctgcctcc	6875
cggggctcaag	cgattctcct	gccttagcct	cccagtagc	tgggactaca	ggcacgcacc	6935
accatgcctg	gctaattttt	gtatttttag	tagacggggg	ttcaccatgc	tggcaggact	6995
gggtctcaaac	tcctgacctt	gtgatctgcc	cgctttagcc	tcccagagtg	ctgggattac	7055
aggcatgagc	caccatgcgt	gggtctttta	aaattttttg	attttttttt	tttttgagac	7115
agagccttgc	tctgtcgccc	aggctggagt	gcagtggcac	gatctcagct	cactacaagc	7175
tcgcgctccc	gggttcacgc	cattcttctg	cctcagcctc	ctgagtagct	gggactacag	7235
gtgcccacca	ccacgcctgg	ctaatttttt	ttgggtattt	tattagagac	aagggttctat	7295
catgttgccc	aggctggctt	caaactcctg	acctcaagtg	atctgcctgc	ctcggcctcc	7355
caaagcgctg	agattacagg	tgtgatctac	tgcgccaggc	ctgggcgtca	tatatcttta	7415
tttgctaagt	ctggcagccc	cacacagaat	aagtagctggg	ggattccata	tccttgtagc	7475
aaagccctgg	gtggagagtc	aggagatgtt	gtagttctgt	ctctgccact	tgcagacttt	7535
gagtttaagc	cagtcgtgct	catgctttcc	ttgctaaata	gaggttagac	cccctatccc	7595
atggtttctc	aggttgcttt	tcagcttgaa	aattgtattc	ctttgtagag	atcagcgtaa	7655
aataattctg	tccttatatg	tggctttatt	ttaatttgag	acagagtgtc	actcagtcgc	7715
ccaggctgga	gtgtggtggg	gcgatcttgg	ctcactgcga	cctccacctc	ccaggttcaa	7775
gcgattctcg	tgcctcaggc	tcccagtag	ctgagattat	agggtgtgtgc	caccaggccc	7835
agctaaactt	tgtattttta	gtagagacag	gggttttgcca	tgttggctaa	gctgggtctcg	7895
aactcctggc	ctcaagtgat	ctgcccgcct	tggcatccca	aagtgtctggg	attacagggtg	7955
tgaaccacca	cacctggcct	caatatagtg	gcttttaagt	gctaaggact	gagatttgtgt	8015
tttgtcagga	agaggccagt	tgtgggtgaa	gcattgctgtg	agagagcttg	tcacctgggt	8075
gaggttgtgg	gagctgcagc	gtgggaactg	gaaagtgggc	tggggatcat	ctttttccag	8135
gtcaggggtc	agccagcttt	tctgcagcgt	gccatagacc	atctcttagc	cctcgtgggt	8195
cagagtctct	gttgcatatt	gtcttttgrt	gtttttcaca	accttttaga	aacataaaaa	8255
gcattcttag	cccgtgggct	ggacaaaaaa	aggccatgac	gggctgtatg	gatttggccc	8315
agcaggccct	tgcttgccaa	gccctgtttt	agacaaggag	cagcttgtgt	gcctggaacc	8375
atcatgggca	caggggagga	gcagagtggg	tgtggagggtg	tgagctggaa	accagggtccc	8435
agagcgctga	gaaagacaga	gggtttttgc	cttgcaagt	agagcaactg	aaatctgaca	8495
ccatccaggt	ccagaaagcc	ctgaagtgtc	gggtggacgct	gcgggggtgct	ccgctctagg	8555
gttacaggga	tgaagatgca	gtctgttagg	gggagtcac	tcacctgttg	gaagatgtga	8615
ttaagaaaag	tagactttca	gggcccggga	tgggtggctca	cgctgtaat	cccagcactt	8675
tgggaggccg	aggcgggtgg	atcacgaggt	caggagatcg	agaccatcct	ggctaacatg	8735
gtgaaacccc	gtctttacta	aaaatacaaa	aaattagctg	ggcgtgggtg	cgggcgcctg	8795
tagtcccagc	tactcgggag	gctgaggcag	gagaatggcg	tgaacctggg	agggtggagct	8855
tgtgtgagc	cgagatcgcg	ccactgcact	ccagcctggg	cgacagagcg	agactccgtc	8915
tcaaaaaaaa	aaaaaaaagt	aggctttcat	gatgtgtgag	ctgaaggcgc	agtaggcaga	8975
agtagaggcc	tcagtccttg	caggagacc	ctcggctctc	atctcctgat	agtcagaccc	9035
agccacactg	gaaagagggg	agacattaca	gcctgcgaga	aaagtaggga	gatttaaaaa	9095
ctgcttggct	ttattttga	actgtttttt	ttgtttgttt	gttttcccca	attcagaata	9155
cagaatactt	ttatggattt	gtttttatta	cttttaattt	gaaacaatat	aatctttttt	9215
ttgttgtttt	tttgagacag	ggctttactc	tgtcacccag	gctgagtga	gtgggtgtgat	9275
cttggctcac	ctcagcctcg	acccctggg	ctcaaatgat	tctcccacct	cagcttccca	9335
agtagctggg	accacagggtg	cgtgtgttgc	gctatacaaa	tcctgaagac	aaggatgctg	9395
ttgctgggtga	tgtcggggat	tcccagatc	ccagatttga	tggcaggatg	cccctgtctg	9455
ctgccttgcc	agggtgccag	gagggcgctg	ctgtggaagc	tgaggcccgg	ccatccaggg	9515
cgatgcattg	ggcgctgatt	cttgttctctg	ctctgcctc	gggtgcttagc	ttttgaaaca	9575
atgaaataaa	ttagaaccag	tgtgaaaatc	gatcagggaa	taaatttaac	gtgggaaataa	9635
actgaacaac	ttagttcttc	ataagagttt	acttggtaaa	tacttgtgat	gaggacaaaa	9695
cgaagcacta	gaaggagagg	cgagtgttag	acctgggtgg	caggagtgtt	ttgtttgttt	9755
tctttggcag	ggtcttgcct	tgttgcctag	gctggagtac	agtggcacaa	tcacagctca	9815
ctatgcctc	gacctcctgg	actcaagcaa	tccctcctgcc	tcagcctccc	agtagctggg	9875
actacaggcg	catgccacca	tgcctggcta	atttttaaatt	tttttttttc	tcttttttga	9935

gatggaatct cactctgtcg cccaggctgg agtgcagtggt cgtgatctcg gctgacggca 9995
agctccgcct cccagggtca ctccattcgc ctgacctcagc ctcccaagta gctgggacta 10055
caggcgctgg gattacaaac ccaaaccctaa agtgcctggga ttacaggcgt gagccactgc 10115
acccggcctg ttttgtcttt caatagcaag agttgtgttt gcttcgcccc tacctttagt 10175
ggaaaaatgt ataaaaatgga gatattgacc tccacattgg ggtggttaaa ttatagcatg 10235
tatgcaaagg agcttcgcta atttaaggct tttttgaaag agaagaaact gaataatcca 10295
tgtgtgtata tatattttta aagccatggg catctttcca tatcagtaaa gctgaggctc 10355
cctgggactg cagagttgtc catcacagtc cattataagt gcgctgctgg gccagggtgca 10415
gtggcttggt cctgaatccc agcactttgg gagggcaagg caggaggatt cattgagccc 10475
aggagttttg aggcgagcct gggcaatgtg gccagacctc atctcttcaa aaaatacaca 10535
aaaaattagc caggcatggg ggcacgtgcc tgtagtctca gctactcagg aggtgaggt 10595
gggaggatca ctttgagcct tgcaggctcaa agctgcagta agccatgac ttgccactgc 10655
attccagcct ggatgacaga gcgagaccct gtctctaaaa aaaaaaaaaa ccaaaccgtg 10715
cactgttttc tttttcttta tcaattttatt atttttaaat taaattttct tttaataatt 10775
tataaattat aaattttatat taaaaaatga caaattttta ttacttatac atgaggtaaa 10835
acttaggata tataaagtac atattgaaaa gtaatttttt ggctggcaca gtggctcaca 10895
cctgtaatcc cagcactttg ggaggccgtg gcgggcagat cacatgagat catgagttcg 10955
agaccaacct gaccaacatg gagagacccc atctctacta aaaatacaaaa attagccggg 11015
gtgggtggcg atgcctgtaa tcccagctac tcgggaggct gaggcaggag aatctcttga 11075
accggggagg cagagggtgc ggtgagccaa gatcgctgct ttgcacacca gcctaggcaa 11135
caagagcgaa agtccgtctc aaaaaaaaag taattttttt taagttaacc tctgtcagca 11195
aacaatttta acccaataaaa ggtctttgtt ttttaagtta gtagaggagt tagggtttat 11255
aaaaaatatg gtagggaagg gggctccctgg atttgctaatt gtgattgtca tttgccctt 11315
aggagagagc tctgttagca gaatgaaaaa attggaagcc agattcaggg agggactgga 11375
agcaaaagaa tttctgttcg aggaagagcc tgatgtttgc cagggtctgt ttaactggac 11435
atgaagagga aggcctctgga ctctcctcca ggagtttcag gagaaggta gggcagtggt 11495
taagagcaga gctctgccta gactagctgg ctgggtactt tgagtggctc cttcagcctg gacctcgggt 11615
agctgggggt tatagtagag atatgggagc acccagcgca ggatcactgt gaacataaat 11675
tcctcacctg aggaagcagg tagagtgggt ctgggtgcat accaagcact ccgtcagtg 11735
cagttaatgg tcgatgatta ggaagcagct taaactagag ggagttgagc tgaatcagga 11795
ttcctgttat aggtagctgg gaatctgcct agcccagtgcc ccagtttatt taggtgctct 11855
ctcagtggtc cctgattgtt ttttcccttg tcatcttacc tacaggatgt gactgggaag 11915
ctctgggttc agtgtcatgt gtctattctt tatttccag gca aag gaa acc aac 11969
Ala Lys Glu Thr Asn
115

aat aag aag aaa gaa ttt gag gaa act gcg aag aaa gtg cgc cgt gcc 12017
Asn Lys Lys Lys Glu Phe Glu Glu Thr Ala Lys Lys Val Arg Arg Ala
120 125 130

atc gag cag ctg gct gcc atg gat tga ggctctggc cggagctgcc 12064
Ile Glu Gln Leu Ala Ala Met Asp
135 140

tggtccacaga gtggctgcac cacttccagg gtttattccc tgggtgccacc agccttctctg 12124
tggtccctctt agcaatgtct taggaaagga gatcaacatt ttcaaattag atgtttcaac 12184
tgtgctcctg ttttgtcttg aaagtggcac cagagggtgct tctgctctg cagcgggtgc 12244
tgctggtaac agtggctgct tctctctctc tctctctttt ttgggggctc atttttgctg 12304
ttttgattcc cgggcttacc aggtgagaag tgaggaggga agaaggcagt gtcccttttg 12364
ctagagctga cagctttgtt cgcgtgggca gagccttcca cagtgaatgt gtctggacct 12424
catgttggtg aggtgtcac agtcttgagt tgggacttgg cagggtgcctg ttgaatctga 12484
gctgcagggt ccttatctgt cacacctgtg cctcctcaga ggacagtttt ttgttggtg 12544
tgtttttttt tttttttttt ttggtagatg catgacttgt gtgtgatgag agaattggaga 12604
cagagtcctt ggctcctcta ctgtttaaca acatggcttt cttattttgt ttgaattgtt 12664
aattcacaga atagcacaata ctacaattaa aactaagcac aaagccattc taagtcattg 12724
gggaaacggg gtgaacttca ggtggatgag gagacagaat agagtgatag gaagcgtctg 12784
gcagatactc cttttgccac tgctgtgtga ttagacaggc ccagttagcc gcggggcaca 12844
tgctggccgc tcctccctca gaaaaaggca gtggcctaaa tcctttttta atgacttggc 12904
tcgatgctgt gggggactgg ctgggctgct gcaggccgtg tgtctgtcag cccaaccttc 12964
acatctgtca cgttctccac acgggggaga gcagcagtcg gcccaggtec ccgctttctt 13024
tgagggcagc agctcccgca gggctgaagt ctggcgtaag atgatggatt tgattcgccc 13084
tcctccctgt catagagctg cagggtggat tgttacagct tcgctggaaa cctctggagg 13144
tcctctcgag tggtcctgag aaataaaaag cctgtcattt caaacactgc tgtggacctt 13204
actgggtttt taaaatattg tcagtttttc atcgtcgtcc ctagcctgcc aacagccatc 13264
tgcccagaca gccgcagtgga ggatgagcgt cctggcagag acgcagttgt ctctggggcg 13324

WO 01/57059

PCT/US01/02939

```

ttgccagagc cacgaacccc agacctgttt gtatcatccg ggctccttcc gggcagaaac 13384
aactgaaaat gcacttcaga cccacttatt tatgccacat ctgagtcggc ctgagataga 13444
cttttccctc taaactggga gaatatcaca gtggtttttg ttagcagaaa atgactcca 13504
gcctctgtac tcatctaagc tgcttatttt tgatatttgt gtcagtctgt aaatggatac 13564
ttcactttaa taactgttgc ttagtaattg gctttgtaga gaagctggaa aaaaatggtt 13624
ttgtcttcaa ctcccttgca tgccaggcgg tgatgtggat ctcggttct gtgagcctgt 13684
gctgtgggca gggctgagct ggagccgcc ctctcagccc gcctgccacg gcctttcctt 13744
aaaggccatc cttaaaacca gacctcatg gctgccagca cctgaaagct tcctcgacat 13804
ctgttaataa agccgtaggc ccttgtctaa gcgcaaccgc ctgactttc tttcagatac 13864
atgtccacat gtccattttt caggttctct aagttggagt ggagtctggg aagggttgtg 13924
aatgaggctt ctgggctatg ggtgagggtc caatggcagg ttagagcccc tcgggccaac 13984
tgccatcctg gaaagtagag acagcagtg ccgctgcccc gaagagacca gcaagccaaa 14044
ctggagcccc cattgcaggc tgcgccatg tggaagagt aactcacaat tgccaataaa 14104
gtctcatgtg gttttatcta cttttttttt ctttttcttt ttttttgaga caaggccttg 14164
ccctcccagg ctggagtga gtggaatgac cacagctcac cgcaacctca aattcttgcg 14224
ttcaagtga cctcccactt tagcctccca agtagctggg actacaggcg cagcccatca 14284
caccgggcta attgaaaaat tttttttttt gtttagatgg aatctcactt tgttgccctg 14344
gctggtctca aactcctggg ctcaagtgat catcctgctt cagcgtccga cttgttggtg 14404
ttataggcgt gagccactgg gcctgaccta gctaccattt tttaatgcag aaatgaagac 14464
ttgtagaaat gaaataactt gtcaggata gtcgaataag taacttttag agctgggatt 14524
tgaacccagg caatctggct ccagagctgg gccctcactg ctgaaggaca ctgtcagctt 14584
gggagggttg ctatggtcgg ctgtctgatt ctaggaggat agggctgtct ttaaagcacc 14644
ccattccatt ttcagacagc tttgtcagaa aggctgtcat atggagctga cacctgcctc 14704
cccaaggctt ccatagatcc tctctgtaca ttgtaacctt ttattttgaa atgaaaattc 14764
acagggaagt gtaaggctag tacaggggat cc 14796

```

<210> 4
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 4
 aaggaccacc gcatctctac a 21

<210> 5
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 5
 ccaagtctgg ctggttctca gt 22

<210> 6
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 6
 cgaggctggc ttcattccact gcc 23

<210> 7
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 7
 gaaggagaag gtcggagtc 19

<210> 8
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 8
 gaagatgggtg atgggatttc

20

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 9
 caagcttccc gttctcagcc

20

<210> 10
 <211> 955
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (109)...(531)

<400> 10
 ggcacgaggg ggccggggct ctcccggcat gctctgccc gcgcctccgc ccgcgcgatt
 tgaatcctgc gtttgagtcg tcttgccgga ggttggtggtg acgccatc atg gga gct
 Met Gly Ala
 1

60

117

ccg gcg ctg ccc cag atc tgg cag ctg tac ctc aag aac tac cgc atc
 Pro Ala Leu Pro Gln Ile Trp Gln Leu Tyr Leu Lys Asn Tyr Arg Ile
 5 10 15

165

gcc acc ttc aag aac tgg ccc ttc ctg gag gac tgc gcc tgc acc cca
 Ala Thr Phe Lys Asn Trp Pro Phe Leu Glu Asp Cys Ala Cys Thr Pro
 20 25 30 35

213

gag cga atg gcg gag gct ggc ttc atc cac tgc cct acc gag aac gag
 Glu Arg Met Ala Glu Ala Gly Phe Ile His Cys Pro Thr Glu Asn Glu
 40 45 50

261

cct gat ttg gcc cag tgt ttt ttc tgc ttt aag gaa ttg gaa ggc tgg
 Pro Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu Leu Glu Gly Trp
 55 60 65

309

gaa ccc gat gac aac ccg ata gag gag cat aga aag cac tcc cct ggc
 Glu Pro Asp Asp Asn Pro Ile Glu Glu His Arg Lys His Ser Pro Gly
 70 75 80

357

tgc gcc ttc ctc act gtc aag aag cag atg gaa gaa cta acc gtc agt
 Cys Ala Phe Leu Thr Val Lys Lys Gln Met Glu Glu Leu Thr Val Ser
 85 90 95

405

gaa ttc ttg aaa ctg gac aga cag aga gcc aag aac aaa att gca aag
 Glu Phe Leu Lys Leu Asp Arg Gln Arg Ala Lys Asn Lys Ile Ala Lys
 100 105 110 115

453

gag acc aac aac aag caa aaa gag ttt gaa gag act gca aag act acc
 Glu Thr Asn Asn Lys Gln Lys Glu Phe Glu Glu Thr Ala Lys Thr Thr
 120 125 130

501

cgt cag tca att gag cag ctg gct gcc taa tgctgagcct ttgctgagat 551
 Arg Gln Ser Ile Glu Gln Leu Ala Ala
 135 140

aacttggacc tgagtgcacat gccacatcta agccacgcat cccagctttt ccagccaggg 611
 cctcctagca ggatcttaga gaaggagaca gtggatattt gaaactggat atcaaatt 671
 tttggttttg ctttaaagtg gctacctctc tttggttttg tggctttgct ctattgtgac 731
 gtggacttaa gcaataagga agtgatgaag ggacagtgtt ctctgacagg acctgtgggg 791
 gtcgggggtgc ctgtgcaagg tcttggttct gattgtgata tttccataca gggctgctaa 851
 tgcagcccat gggtaagtgt ggttatatgt gtttgtgctg ataattttgt cctgatgagt 911
 tttcctacca cggggtaacg gaataaaatc acttgaaaaa gtgg 955

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 11
 ccgagaacga gcctgatttg 20

<210> 12
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 12
 gggagtgcctt tctatgctcc tcta 24

<210> 13
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 13
 taaggaattg gaaggctggg aacccg 26

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 14
 ggcaaattca acggcacagt 20

<210> 15
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 15
 gggctctcgtc cctggaagct 20

<210> 16
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 16
aaggccgaga atgggaagct tgtcatc 27

<210> 17
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 17
gcgattcaaa tctggcgg 18

<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 18
cctctgccaa cgggtccc 18

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19
tgagaaaggg ctgccagg 18

<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20
ttcttgaatg tagagatg 18

<210> 21
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21
ggcgcagccc tccaagaa 18

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22
caagtctggc tcgttctc 18

<210> 23
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23
tccagctcct tgaagcag

<210> 24
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24
ggtcgtcatc tggctccc

<210> 25
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25
gcttcttgac agaaagga

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26
ggttaattct tcaaactg

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27
tcttggtctt ttctctgt

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28
tcttattggt gggttcct

<210> 29
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

18

18

18

18

18

18

<400> 29
tcgcagtttc ctcaaatt 18

<210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30
cgatggcacg gcgcactt 18

<210> 31
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31
cctggaagtg gtgcagcc 18

<210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32
acaggaaggc tggtagca 18

<210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33
tttgaaaatg ttgatctc 18

<210> 34
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34
acagttgaaa catctaatt 18

<210> 35
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35
ctttcaagac aaaacagg 18

<210> 36
<211> 18
<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36
acaggcagaa gcacctct 18

<210> 37
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37
aagcagccac tgttacca 18

<210> 38
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38
aaagagagag agagagag 18

<210> 39
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39
tcctcactt ctcacctg 18

<210> 40
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40
agggacactg ccttcttc 18

<210> 41
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41
ccacgcgaac aaagctgt 18

<210> 42
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42
actgtggaag gctctgcc 18

<210> 43
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43
aggactgtga cagcctca 18

<210> 44
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
tcagattcaa caggcacc 18

<210> 45
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45
attctctcat cacacaca 18

<210> 46
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46
tggtgttaaa cagtagag 18

<210> 47
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47
tgtgctattc tgtgaatt 18

<210> 48
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 48
gacttagaat ggctttgt 18

<210> 49
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 49
ctgtctctctc atccacct 18

<210> 50
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 50
aaaaggagta tctgccag 18

<210> 51
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 51
gaggagcggc cagcatgt 18

<210> 52
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 52
ggctgacaga cacacggc 18

<210> 53
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 53
ccgtgtggag aacgtgac 18

<210> 54
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 54
tacgccagac ttcagccc 18

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 55
atgacagga ggaggcg 18

WO 01/57059

PCT/US01/02939

<210> 56
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 56
 gccgagatga cctccaga 18

 <210> 57
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 57
 gcgattcaaa tctggcgg 18

 <210> 58
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 58
 cctctgccaa cgggtccc 18

 <210> 59
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 59
 tgagaaaggg ctgccagg 18

 <210> 60
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 60
 ttcttgaatg tagagatg 18

 <210> 61
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 61
 ggcgcagccc tccaagaa 18

 <210> 62
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

<400> 62
caagtctggc tcgttctc -- 18

<210> 63
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 63
tccagctcct tgaagcag 18

<210> 64
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 64
ggctgctatc tggctccc 18

<210> 65
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 65
gcttcttgac agaaagga 18

<210> 66
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 66
ggttaattct tcaaactg 18

<210> 67
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 67
tcttggtctt ttctctgt 18

<210> 68
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 68
tcttattggt gggttcct 18

<210> 69
<211> 18
<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 69 18
tcgcagtttc ctcaaatt

<210> 70
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 70 18
cgatggcacg gcgcactt

<210> 71
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 71 18
cctggaagtg gtgcagcc

<210> 72
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 72 18
acaggaaggc tggaggca

<210> 73
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 73 18
tttgaaaatg ttgatctc

<210> 74
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 74 18
acagttgaaa catctaata

<210> 75
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 75 18
ctttcaagac aaaacagg

<210> 76
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 76
acaggcagaa gcacctct 18

<210> 77
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 77
aagcagccac tgttacca 18

<210> 78
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 78
aaagagagag agagagag 18

<210> 79
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 79
tccctcactt ctcacctg 18

<210> 80
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 80
agggacactg ccttcttc 18

<210> 81
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 81
ccacgcgaac aaagctgt 18

<210> 82
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 82
actgtggaag gctctgcc 18

<210> 83
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 83
aggactgtga cagcctca 18

<210> 84
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 84
tcagattcaa caggcacc 18

<210> 85
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 85
attctctcat cacacaca 18

<210> 86
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 86
tgttgttaaa cagtagag 18

<210> 87
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 87
tgtgctattc tgtgaatt 18

<210> 88
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 88
gacttagaat ggctttgt 18

<210> 89
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 89
ctgtctctc atccacct 18

<210> 90
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 90
aaaaggagta tctgccag 18

<210> 91
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 91
gaggagcggc cagcatgt 18

<210> 92
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 92
ggctgacaga cacacggc 18

<210> 93
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 93
ccgtgtggag aacgtgac 18

<210> 94
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 94
tacgccagac ttcagccc 18

<210> 95
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 95
 atgacagggga ggagggcg 18

<210> 96
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 96
 gccgagatga cctccaga 18

<210> 97
 <211> 1619
 <212> DNA
 <213> Homo sapiens

<400> 97
 ccgccagatt tgaatcgcg gacccgttgg cagaggtggc ggccggcgca tgggtgcccc 60
 gacgttgccc cctgcctggc agccctttct caaggaccac cgcattctcta cattcaagaa 120
 ctggcccttc ttggagggct gcgcctgcac cccggagcgg atggccgagg ctggcttcat 180
 ccactgcccc actgagaacg agccagactt ggcccagtggt ttcttctgct tcaaggagct 240
 ggaaggctgg gagccagatg acgaccccat agaggaacat aaaaagcatt cgtccgggtg 300
 cgcttttctt tctgtcaaga agcagtttga agaattaacc cttggtgaat ttttgaaact 360
 ggacagagaa agagccaaga acaaaattgc aaaggaaaacc aacaataaga agaaagaatt 420
 tgaggaaaact gcgaagaaag tgcgccgtgc catcgagcag ctggctgccca tggattgagg 480
 cctctggccg gagctgcctg gtcccagagt ggctgcacca cttccagggt ttattccctg 540
 gtgccaccag ccttctctgtg ggccccttag caatgtctta ggaaaggaga tcaacatttt 600
 caaatttagat gtttcaactg tgctcctggt ttgtcttgaa agtggcacca gaggtgcttc 660
 tgctctgtgca gcgggtgctg ctggtaacag tggtctcttc tctctctctc tctctttttt 720
 gggggctcat ttttgtctgt ttgattcccc ggcttaccag gtgagaagtg agggaggaag 780
 aaggcagtggt cccttttgct agagctgaca gctttgttcg cgtgggcaga gccttcaca 840
 gtgaatgtgt ctggacctca tgttgttgag gctgtcacag tcttgagtggt ggacttggca 900
 ggtgcctgtt gaatctgagc tgcaggttcc ttatctgtca cacctgtgcc tctcagagg 960
 acagtttttt tgttgttgtg tttttttgtt tttttttttt ggtagatgca tgacttgtgt 1020
 gtgatgagag aatggagaca gagtccctgg ctccctact gtttaacaac atggctttct 1080
 tattttgttt gaattgttaa ttcacagaat agcacaaaact acaattaaaa ctaagcaca 1140
 agccattcta agtcattggg gaaacgggggt gaacttcagg tggatgagga gacagaatag 1200
 agtgatagga agcgtctggc agatactcct tttgccactg ctgtgtgatt agacaggccc 1260
 agtgagccgc ggggcacatg ctggccgctc ctccctcaga aaaaggcagt ggcctaaatc 1320
 ctttttaaat gacttggctc gatgctgtgg gggactggct gggctgctgc aggcgtgtg 1380
 tctgtcagcc caaccttcac atctgtcacg ttctccacac gggggagaga cgcagtcgc 1440
 ccaggtcccc gctttctttg gaggcagcag ctcccgcagg gctgaagtct ggcgtaagat 1500
 gatggatttg attcgccctc ctccctgtca tagagctgca ggggtggattg ttacagcttc 1560
 gctggaaacc tctggaggtc atctcggctg ttcttgagaa ataaaaagcc tgtcatttc 1619

<210> 98
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 98
 gccaacgggt cccgcgat 18

<210> 99
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 99
 catgccgccc cgcacc 18

<210> 100
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 100
agatgcggtg gtccttga 18

<210> 101
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 101
gggccagttc ttgaatgt 18

<210> 102
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 102
tggatgaagc cagcctcg 18

<210> 103
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 103
gcagaagaaa cactgggc 18

<210> 104
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 104
ccagccttcc agctcctt 18

<210> 105
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 105
caaccggacg aatgcttt 18

<210> 106
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 106
gacagaaagg aaagcgca 18

<210> 107
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 107
tcaaactgct tcttgaca 18

<210> 108
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 108
accaagggtt aattcttc 18

<210> 109
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 109
ggctctttct ctgtccag 18

<210> 110
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 110
atattgttct tggctctt 18

<210> 111
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 111
tttcttctta ttgttggt 18

<210> 112
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 112
gtttcctcaa attctttc 18

<210> 113
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 113
ttcttcgcag tttcctca

18

<210> 114
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 114
cacggcgac tttcttcg

18

<210> 115
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 115
agctgctcga tggcacgg

18

<210> 116
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 116
ccactctggg accaggca

18

<210> 117
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 117
aaccctggaa gtggtgca

18

<210> 118
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 118
tggcaccagg gaataaac

18

<210> 119
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 119
tcctaagaca ttgctaag

18

<210> 120
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 120
tgttgatctc ctttccta

18

<210> 121
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 121
taatttgaaa atgttgat

18

<210> 122
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 122
tgaaacatct aatttgaa

18

<210> 123
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 123
aacaggagca cagttgaa

18

<210> 124
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 124
agacaaaaca ggagcaca

18

WO 01/57059

PCT/US01/02939

<210>	125	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	125	
	tgccactttc aagacaaa	18
<210>	126	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	126	
	tctggtgccca ctttcaag	18
<210>	127	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	127	
	tgcacaggca gaagcacc	18
<210>	128	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	128	
	ccactgttac cagcagca	18
<210>	129	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	129	
	aaaagagaga gagagaga	18
<210>	130	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	130	
	cttcttcttc cctcactt	18

<210> 131
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 131
agctctagca aaagggac

18

<210> 132
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 132
ctctgcccac gcgaacaa

18

<210> 133
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 133
cagacacatt cactgtgg

18

<210> 134
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 134
tcaacaacat gaggtcca

18

<210> 135
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 135
gccaaagcca cactcagg

18

<210> 136
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 136
gaggagccag ggactctg

18

<210> 137
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 137
aataagaaag ccatgttg 18

<210> 138
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 138
acaattcaaa caaaataa 18

<210> 139
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 139
aacaattcaa acaaaata 18

<210> 140
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 140
taacaattca aacaaaat 18

<210> 141
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 141
ttaacaattc aaacaaaa 18

<210> 142
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 142
attaacaatt caaacaaa 18

<210> 143
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 143
aattaacaat tcaaacaa

18

<210> 144
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 144
ttctgtgaat taacaatt

18

<210> 145
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 145
attctgtgaa ttaacaat

18

<210> 146
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 146
tattctgtga attaacaa

18

<210> 147
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 147
ctattctgtg aattaaca

18

<210> 148
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 148
gctattctgt gaattaac

18

WO 01/57059

PCT/US01/02939

<210> 149
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 149
tgctattctg tgaattaa 18

<210> 150
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 150
gtgctattct gtgaatta 18

<210> 151
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 151
ttgtgctatt ctgtgaat 18

<210> 152
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 152
tttgtgctat tctgtgaa 18

<210> 153
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 153
gtttgtgcta ttctgtga 18

<210> 154
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 154
agtttgtgct attctgtg 18

<210> 155
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 155
tagtttgtgc tattctgt

18

<210> 156
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 156
gtagtttgtg ctattctg

18

<210> 157
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 157
tgtagtttgt gctattct

18

<210> 158
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 158
ttgtagtttg tgctattc

18

<210> 159
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 159
attgtagttt gtgctatt

18

<210> 160
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 160
aattgtagtt tgcttat

18

WO 01/57059

PCT/US01/02939

<210>	161	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	161	
	taattgtagt ttgtgcta	18
<210>	162	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	162	
	tgcttagttt taattgta	18
<210>	163	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	163	
	ccccaatgac ttagaatg	18
<210>	164	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	164	
	cctgaagttc accccggt	18
<210>	165	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	165	
	tctattctgt ctctcat	18
<210>	166	
<211>	18	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	166	
	gacgcttcct atcactct	18

<210> 167
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 167
agtggcaaaa ggagtatc

18

<210> 168
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 168
ctgtctaadc acacagca

18

<210> 169
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 169
tgagggagga gcggccag

18

<210> 170
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 170
gcagcccagc cagtcacc

18

<210> 171
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 171
aggttgggct gacagaca

18

<210> 172
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 172
ggagaacgtg acagatgt

18

WO 01/57059

PCT/US01/02939

<210> 173
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 173
gggcggactg cgtctctc

18

<210> 174
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 174
cttcagccct gcgggagc

18

<210> 175
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 175
ccatcatctt acgccaga

18

<210> 176
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 176
agggaggagg gcgaatca

18

<210> 177
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 177
atttctcagg aacagccg

18

<210> 178
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 178
agagccccgg cccctcgtg

20

<210> 179
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 179
gagagccccg gccccctcgt 20

<210> 180
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 180
agagcatgcc gggagagccc 20

<210> 181
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 181
gcgcgccgca gagcatgccg 20

<210> 182
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 182
aaacgcagga ttcaaactgc 20

<210> 183
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 183
caagacgact caaacgcagg 20

<210> 184
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 184
gccaagacga ctcaaacgca 20

<210> 185
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 185
catgatggcg tcaccacaac 20

<210> 186
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 186
cggagctccc atgatggcgt 20

<210> 187
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 187
cgccggagct cccatgatgg 20

<210> 188
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 188
ggaagggcca gttcttgaag 20

<210> 189
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 189
gcgcagtcct ccaggaagg 20

<210> 190
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 190
aggcgagtc ctccaggaag 20

<210> 191
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 191
aggcgagtc ctccaggaag 20

<210> 192
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 192
tgcaggcgca gtcctccagg 20

<210> 193
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 193
aatcaggctc gttctcgga 20

<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 194
cactgggcca aatcaggctc 20

<210> 195
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 195
cagccttcca attccttaa 20

<210> 196
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 196
catcggttc ccagccttc 20

WO 01/57059

PCT/US01/02939

<210> 197
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 197
 tgtcatcggg ttcccagcct

20

<210> 198
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 198
 cctctatcgg gttgtcatcg

20

<210> 199
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 199
 gctttctatg ctctctatc

20

<210> 200
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 200
 ttgacagtga ggaaggcgca

20

<210> 201
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 201
 ttcttccatc tgcttcttga

20

<210> 202
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 202
 cactgacggt tagttcttcc

20

<210> 203
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 203
ttcactgacg gtagttctt

20

<210> 204
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 204
aagaattcac tgacggtag

20

<210> 205
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 205
tcaagaattc actgacggtt

20

<210> 206
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 206
cttcaaactc tttttgcttg

20

<210> 207
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 207
ctcaattgac tgacggtag

20

<210> 208
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 208
gctcaattga ctgacgggta

20

WO 01/57059

PCT/US01/02939

<210>	209	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	209	
	tgctcaattg actgacgggt	20
<210>	210	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	210	
	ggctcagcat taggcagcca	20
<210>	211	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	211	
	tctcagcaaa ggctcagcat	20
<210>	212	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	212	
	gctaggaggc .cctggctgga	20
<210>	213	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	213	
	ctctaagatc ctgctaggag	20
<210>	214	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<223>	Antisense Oligonucleotide	
<400>	214	
	accactgtct ccttctctaa	20

<210> 215
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 215
atccagtttc aaaataccac 20

<210> 216
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 216
atttgatatc cagtttcaaa 20

<210> 217
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 217
aaagcaaac caaaaatatt 20

<210> 218
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 218
agagaggtag ccactttaa 20

<210> 219
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 219
accaaagaga ggtagccact 20

<210> 220
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 220
cgtcacaata gagcaaagcc 20

WO 01/57059**PCT/US01/02939**

<210> 221
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 221
taagtccacg tcacaataga

20

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 222
ttcatcactt ccttattgct

20

<210> 223
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 223
agagaacact gtcccttcat

20

<210> 224
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 224
acaggcaccc cgacccccac

20

<210> 225
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 225
gaaccaagac cttgcacagg

20

<210> 226
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 226
tatcacaatc agaaccaaga

20

<210> 227
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 227
 cattagcagc cctgtatgga 20

 <210> 228
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 228
 aaccacactt acccatgggc 20

 <210> 229
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 229
 gtggtaggaa aactcatcag 20

 <210> 230
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <223> Antisense Oligonucleotide

 <400> 230
 actttttcaa gtgattttat 20

 <210> 231
 <211> 515
 <212> DNA
 <213> Mus musculus

 <223>

 <220>
 <221> unsure
 <222> 266
 <223> unknown
 <220>
 <221> CDS
 <222> (301)...(384)

 <400> 231
 ttcggtacct tggctgggat taaaggtgtg agccaccacg cccggcttga aaaaacatgt 60
 ttatatatat atatgtatat atataaaaaa tcaagggaagg aaaattccag tttgtagctc 120
 agtaagtatt tgcttattac tattgaggcc ctaggttcaa ttcccagcaa tacaaaaata 180
 ataactttcc ttttaatgat ttatcttgcc acgatggtga tgacactagc atctcaccct 240
 ggacaggcaa gcctggccct ctggcnaccc cagcccttgc gtgtctgttc atcattccag 300
 gca aag gag acc aac aac aag caa aaa gag ttt gaa gag act gca aag 348

WO 01/57059

PCT/US01/02939

Ala	Lys	Glu	Thr	Asn	Asn	Lys	Gln	Lys	Glu	Phe	Glu	Glu	Thr	Ala	Lys	
1				5				10						15		

act acc cgt cag tca att gag cag ctg gct gcc taa tgctgagcct	394
Thr Thr Arg Gln Ser Ile Glu Gln Leu Ala Ala	
20 25	

ttgctgagat aacttggacc tgagtgcacat gccacatcta agccacgcat cccagctttt	454
ccagccaggg cctcctagca ggatcttaga gcaggagaca gtgggtatttt gaaactggat	514
a	515

<210> 232
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 232
 aatcccagcc aaggatccga 20

<210> 233
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 233
 cgtgggtggct cacaccttta 20

<210> 234
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 234
 tttcaagccg ggcgtgggtgg 20

<210> 235
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 235
 acatatatat atataaacat 20

<210> 236
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 236
 aattttcctt ccttgatttt 20

<210> 237
 <211> 20

<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 237
tactgagcta caaactggaa 20

<210> 238
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 238
acttactgag ctacaaactg 20

<210> 239
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 239
aagttattat ttttgtattg 20

<210> 240
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 240
aaagttatta tttttgtatt 20

<210> 241
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 241
taaatcatta aaaggaaagt 20

<210> 242
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 242
catcgtggca agataaatca 20

<210> 243
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 243

WO 01/57059

PCT/US01/02939

gcctgtccag ggtgagatgc	20
<210> 244	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 244	
ttgcctgtcc aggggtgagat	20
<210> 245	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 245	
gggccaggct tgcctgtcca	20
<210> 246	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 246	
ggtctccttt gcctggaatg	20
<210> 247	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 247	
gttggtctcc tttgcctgga	20
<210> 248	
<211> 18	
<212> DNA	
<213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 248	
taagctgttc tatgtgtt	18
<210> 249	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> unsure	
<222> (1)..(20)	
<223> Antisense Oligonucleotide	
<400> 249	
nnnnnnnnnn nnnnnnnnnn	20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/2939

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; A61K 48/00; C12N 15/09, 15/00; C12Q 1/68

US CL : 435/6, 375, 455; 514/44; 536/23.1, 24.1, 24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 375, 455; 514/44; 536/23.1, 24.1, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, MEDLINE, BIOSIS, EMBASE, CAPLUS, BIOTECHNO

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/22589 A2 (YALE UNIVERSITY) 28 May 1998, see entire document.	1, 2, 5-15, 20
---		-----
A		3, 4, 16-19, 21-30

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 MAY 2001

Date of mailing of the international search report

20 JUN 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SEAN MCGARRY

Telephone No. (703) 308-0196